Published in final edited form as:

Bioorg Med Chem. 2012 March 15; 20(6): 2067–2081. doi:10.1016/j.bmc.2012.01.038.

Synthesis and Pharmacology of 1-Alkyl-3-(1-naphthoyl)indoles: Steric and Electronic Effects of 4- and 8-Halogenated Naphthoyl Substituents.

Jenny L. Wiley^{a,c}, Valerie J. Smith^b, Jianhong Chen^b, Billy R. Martin^c, and John W. Huffman^{*,b,d}

^aRTI International, P.O. Box 12194, Research Triangle Park, NC 27709-2194

^bHoward L. Hunter Laboratory, Clemson University, Clemson, SC 29634-0973

^cDepartment of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298-0613

^dP.O. Box 695, Dillsboro, NC 28725-0695

Abstract

To develop SAR at both the cannabinoid CB₁ and CB₂ receptors for 3-(1-naphthoyl)indoles bearing moderately electron withdrawing substituents at C-4 of the naphthoyl moiety, 1-propyl and 1-pentyl-3-(4-fluoro, chloro, bromo and iodo-1-naphthoyl) derivatives were prepared. To study the steric and electronic effects of substituents at the 8-position of the naphthoyl group, the 3-(4-chloro, bromo and iodo-1-naphthoyl)indoles were also synthesized. The affinities of both groups of compounds for the CB₁ and CB₂ receptors were determined and several of them were evaluated in vivo in the mouse. The effects of these substituents on receptor affinities and in vivo activity are discussed and structure-activity relationships are presented. Although many of these compounds are selective for the CB₂ receptor, only three JWH-423, 1-propyl-3-(4-iodo-1-naphthoyl)indole, JWH-422, 2-methyl-1-propyl-3-(4-iodo-1-naphthoyl)indole, the 2-methyl analog of JWH-423 and JWH-417, 1-pentyl-3-(8-iodo-1-naphthoyl)indole, possess the desirable combination of low CB₁ affinity and good CB₂ affinity.

Keywords

cannabinoids; structure-activity relationships; cannabinoid receptors; aminoalkylindole

1. Introduction

In the four decades since Gaoni and Mechoulam reported the elucidation of the structure of Δ^9 -tetrahydrocannabinol (**1**, THC), the principal psychoactive constituent of marijuana,¹ comprehensive structure-activity relationships (SAR) have been developed based upon the dibenzopyran nucleus of THC.²⁻⁶ The pharmacological effects of cannabinoids are

© 2012 Elsevier Ltd. All rights reserved.

*Corresponding Author: John W. Huffman, Mailing Address: PO Box 695, Dillsboro, NC 28725-0695, Telephone: 828-631-3339, Fax: 864-656-6613, Huffman@clemson.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

considered to be mediated through at least two G-protein-coupled, transmembrane receptors. One of these, the CB₁ receptor, is found predominantly in the central nervous system and is thought to be responsible for most of the overt pharmacological effects of cannabinoids.^{5,7-9} A second receptor, designated CB₂, was originally identified from macrophages present in the spleen, and is expressed primarily in the periphery.¹⁰

In 1991 a group at Sterling-Winthrop reported that pravadoline (**2**) and a number of other structurally similar indole derivatives inhibited contractions of the electrically stimulated mouse vas deferens.¹¹ Subsequent work revealed that these compounds also inhibit adenylate cyclase, are antinociceptive and interact with a G-coupled protein in the brain. It was also found that these aminoalkylindoles exhibit typical cannabinoid pharmacology in vivo and that the G-coupled protein with which they interact is the cannabinoid CB₁ receptor.^{12,13} One of these aminoalkylindoles, WIN-55,212-2 (**3**), developed by the Winthrop group, is not only very potent in vivo, but has high affinity for both the cannabinoid CB₁ and CB₂ receptors.^{14,15} The Winthrop group synthesized more than 100 aminoalkylindoles and proposed preliminary SAR.^{12,13,16} These SAR included the observation that a group larger than methyl at C-2 of the indole nucleus greatly attenuates potency and that a bicyclic aroyl group, usually 1-naphthoyl or a substituted 1-naphthoyl group, at C-3 of the indole is essential for potency. They also concluded that an aminoalkyl group, usually substituted aminoethyl, attached to the indole nitrogen was essential for cannabinoid activity.

In 1994 we reported that the aminoalkyl group appended to the indole nitrogen could be replaced by an alkyl group to provide relatively simple indole derivatives that exhibit typical cannabinoid pharmacology.¹⁷ In particular, JWH-018, 1-pentyl-3-(1-naphthoyl)indole (**4**) has high affinity ($K_i = 9 \pm 5$ nM) for the CB₁ receptor and exhibits typical cannabinoid pharmacology in vivo.¹⁸ 1-propyl-2-methyl-3-(1-naphthoyl)indole JWH-015 (**5**) has relatively high affinity for the CB₂ receptor ($K_i = 13.8 \pm 4.6$ nM), modest affinity for the

CB₁ receptor ($K_i = 164 \pm 22$ nM) and was one of the first compounds found to have useful selectivity for the CB₂ receptor.¹⁵

In subsequent work directed toward the development of improved CB₂ cannabinoid receptor ligands and to establish SAR for cannabimimetic indoles at both the CB₁ and CB₂ receptors, a number of additional indole derivatives were prepared and their pharmacology was evaluated.^{19,20,21} It was found that CB₁ receptor affinity is optimal with a 1-pentyl nitrogen substituent and decreases dramatically with *N*-alkyl substituents of three or less carbon atoms or more than six carbon atoms. In agreement with the observations of the Winthrop group, a 2-methyl substituent (for numbering see structure **4**) slightly decreases affinity at the CB₁ receptor, while larger substituents at this position decrease CB₁ receptor affinity considerably.^{14,16,20} A small 4-alkyl-1-naphthoyl group at C-3 of the indole, as in JWH-213 (**6**) enhances both CB₁ ($K_i = 1.5 \pm 0.2$ nM) and CB₂ receptor affinity ($K_i = 0.42 \pm 0.05$ nM), while a 7-methyl or ethyl-1-naphthoyl substituent as in JWH-048 (**7**) and JWH-262 (**8**) has relatively little effect on affinity for either receptor.^{20,21} The effect upon CB₁ and CB₂ receptor affinity of methoxy substituents at C-2, C-4, C-6 and C-7 of the 1-naphthoyl moiety has also been described. A 2- or 6-methoxy-1-naphthoyl group greatly attenuates affinity for the CB₁ receptor, but has little effect upon CB₂ affinity. A 4-methoxy-1-naphthoyl group enhances affinity for both receptors while a 6-methoxy substituent reduces CB₁ receptor affinity significantly, but has only a slight effect upon CB₂ binding. A 7-methoxy group has relatively little effect upon affinity for either receptor.^{20,21}

13 R = C₃H₇ or C₅H₁₁

14 X = Cl
15 X = Br
16 X = I

These studies provide some indication of the effect of various naphthoyl substituents upon the CB₁ and CB₂ receptor affinities of 1-pentyl and 1-propyl-3-(1-naphthoyl)indoles. However, all of the substituents on the naphthoyl moiety examined to date are weakly to moderately electron releasing. In order to explore the effect upon receptor affinity of electron withdrawing substituents at C-4 of the naphthoyl, 1-propyl- and 1-pentyl-3-(1-naphthoyl-4-halo)indoles (**9** to **12**, R = C₃H₇ or C₅H₁₁, R' = H or CH₃) were synthesized and their pharmacology was evaluated. In earlier work it was found that 1-propyl- and 1-pentyl-2-methyl-3-(2-methoxy-1-naphthoyl)indoles (**13**) had restricted rotation about the naphthalene C-1 bond to the carbonyl carbon, with a calculated energy barrier of 12.9 kcal/mol and an experimentally determined barrier of 13.1 kcal/mol.²⁰ In addition, two of the compounds in this series were very selective for the CB₂ receptor. It seemed probable that the 3-(8-halogenated-1-naphthoyl)indole derivatives (**14** to **16**, R = C₃H₇ or C₅H₁₁, R' = H or CH₃) would exhibit similar restricted rotation, would be readily available and would provide a second series of indole derivatives with electron withdrawing groups on the naphthalene moiety, providing additional insight into the SAR of the cannabimimetic indoles. The choice of the *N*-propyl substituent is based on the observation that JWH-015 (**5**), a highly CB₂ selective indole derivative, contains this substitution pattern.^{15,19} The *N*-

pentyl group was chosen since this substituent almost invariably provides compounds with higher CB₁ receptor affinities than are observed with other nitrogen substituents.

2. Results

As shown in Scheme 1, two synthetic protocols have been developed for the preparation of various 1-alkyl-3-(1-naphthoyl)indoles. In one of the schemes, indole or 2-methylindole (**17**, R = H or CH₃) is reacted with methylmagnesium bromide and the resulting ambident anion upon reaction with the aroyl chloride provides 3-acylindole **18**.^{11,17} Alkylation on nitrogen is effected using a primary alkyl halide with KOH in DMSO to afford the target 3-acylindole (**19**). Although this sequence is satisfactory and uses readily available aroyl chlorides, the yields in the first step are quite variable and intermediate **18** is difficult to purify. Alternatively, acylation of an *N*-substituted indole or 2-methylindole (**20**) using an acyl chloride and dimethylaluminum chloride provides the 3-acylindole in from fair to good yield.²⁰ In this procedure, which was developed by Okauchi, the indole is stirred with the Lewis acid for 30 min prior to addition of the acyl chloride.²² Although this procedure appears to be a modified Friedel-Crafts reaction, there is evidence that it proceeds via a 3-indolylaluminum intermediate.²³ Unless otherwise noted, cannabimimetic indoles **9** to **12** and **14** to **16** were prepared via the Okauchi procedure.

For the synthesis of the 4-halogenated naphthoylindoles (**9** to **12**), 4-fluoro-1-naphthoic acid (**21**, Scheme 2) is the only 4-halo-1-naphthoic acid that is commercially available. 4-Chloro-, 4-bromo and 4-iodo-1-naphthoic acids (**22**) were synthesized as shown in Scheme 2. Friedel-Crafts acylation of 1-chloro, 1-bromo or 1-iodonaphthalene (**23**) with acetyl chloride under standard reaction conditions provided the corresponding 4-halogenated-1-acetylnaphthalene (**24**). Reaction of ketones **24** with iodine and pyridine under the conditions of the King reaction gave pyridinium salts **25**, which upon basic hydrolysis and acidification provided acids **22**.²⁴ For purification acids **22** were converted to the corresponding methyl esters under standard conditions and the esters were purified by chromatography. Basic hydrolysis and acidification provided pure acids **22**.

JWH-414 (**9**, R = C₃H₇, R' = H), JWH-415 (**9**, R = C₃H₇, R' = CH₃), JWH-412 (**9**, R = C₅H₁₁, R' = H), JWH-413 (**9**, R = C₅H₁₁, R' = CH₃) were prepared from the acid chloride derived from commercial 4-fluoro-1-naphthoic acid by direct acylation of the appropriate indole. In the 3-(4-chloro-1-naphthoyl)indole series, the 1-propyl compound (**10**, JWH-400, R = C₃H₇, R' = H) was prepared both by direct acylation of 1-propylindole and via alkylation of 3-(4-chloro-1-naphthoyl)indole. JWH-399 (**10**, R = C₃H₇, R' = CH₃), JWH-398 (**10**, R = C₅H₁₁, R' = H) and JWH-397 (**10**, R = C₅H₁₁, R' = CH₃) were synthesized by alkylation of the requisite 3-acylindole. The four 3-(4-bromo-1-naphthoyl)indoles (**11**, JWH-386, JWH-395, JWH-387 and JWH-394) were prepared by both routes, while the 3-(4-iodo-1-naphthoyl)indoles (**12**, JWH-423, JWH-422, JWH-421 and JWH-420) were prepared by the acylation of the appropriate *N*-alkylindole with 4-iodo-1-naphthoyl chloride.

The substituted 1-naphthoic acids (**26**, **27** and **28**) needed for the synthesis of 3-(8-halo-1-naphthoyl)indoles **14** to **16** were prepared from anhydro-8-(hydroxymercuri)-1-naphthoic acid (**29**) by a modification of the sequence reported by Whitmore many years ago and developed some years later by Shechter's group (Scheme 3).^{25,26} The starting material, anhydro-8-(hydroxymercuri)-1-naphthoic acid, is prepared from 1,8-naphthoic anhydride (**30**) by treatment of the bis-sodium salt with mercuric acetate. For the preparation of 8-bromo-(**27**) and 8-iodo-1-naphthoic acid (**28**), treatment of anhydro acid **29** with an aqueous solution of sodium bromide (for the preparation of acid **15**) or potassium iodide (for the

preparation of acid **16**) followed by addition of the appropriate halogen provided acids **27** and **28**.

Although Whitmore reported that reaction of **29** with chlorine in glacial acetic acid gave 8-chloro-1-naphthoic acid (**26**),²⁵ Shechter found that this reaction afforded 5,8-dichloro-1-naphthoic acid as the major product²⁶ and in another early paper Rule and Barrett reported that chloromercuri compound **31** gave pure acid **26** in modest yield (31%) using Whitmore's procedure.²⁷ Acceptable yields of 8-chloro-1-naphthoic acid (**26**) were ultimately obtained using chlorine in acetic acid and carrying out the reaction at ice bath temperatures in acetic acid-dichloromethane.²⁸ In view of the rather lengthy synthesis of 8-fluoro-1-naphthoic acid, this compound was not prepared.²⁹

The four 3-(8-chloro-1-naphthoyl)indoles (JWH-456, JWH-461, JWH-457, JWH-462), the 8-bromo analogs (JWH-428, JWH-429, JWH-424, JWH-425) and the 3-(8-iodo-1-naphthoyl)indoles (JWH-419, JWH-418, JWH-416 and JWH-417) were all prepared by the direct acylation of the appropriately substituted indole. In contrast to the 1-alkyl-3-(2-methoxy-1-naphthoyl)indole series, in which only those compounds derived from 2-methylindole (**13**) indicated restricted rotation about the naphthyl C-1 bond and the carbonyl carbon,²⁰ the ¹H NMR spectra of all of the 1-alkyl-3-(8-halo-1-naphthoyl)indoles (**14** to **16**) showed evidence of restricted rotation. Variable temperature ¹H NMR experiments from ambient temperature to 110 °C were carried out on several of these compounds and the data for 1-propyl-3-(8-bromo-1-naphthoyl)indole (JWH-428, **15**, R = C₃H₇, R' = H) and its 2-methyl analog (JWH-429, **15**, R = C₃H₇, R' = CH₃) are typical. At ambient temperature for **15** (R = C₃H₇, R' = H) the methylene group adjacent to nitrogen appears as a multiplet at δ 4.14-4.18, while at 100 °C it is a well resolved triplet, *J* = 7.5 Hz, at δ 4.15. Also, in the aromatic region of the spectrum at ambient temperature, signals for two protons are absent. The differences in the spectra at ambient temperature and 100 °C for **15** (R = C₃H₇, R' = CH₃) are considerably more pronounced with several protons giving rise to signals of reduced intensity at ambient temperature and the signal for the C-2 methyl group was absent. The signal for this methyl group was also absent at 75 °C, but appeared as a broadened singlet at 100 °C (see the Experimental).³⁰

The affinities of the 4- and 8-halonaphthoylindoles for the CB₁ and CB₂ receptors were determined by measuring their ability to displace the potent cannabinoid [³H] CP-55,940 from its binding site in cloned human receptor preparations using the procedure described by Martin et al.³¹ The results of these determinations are summarized in Tables 1 and 2. Also included in Table 1 are the receptor affinities for Δ⁹-THC (**1**) and WIN-55,212-2 (**3**). The *in vivo* pharmacology was evaluated using the mouse model of cannabinoid activity, which measures spontaneous activity (SA), antinociception (as tail flick, TF), rectal temperature (RT) and catalepsy (as ring immobility).^{32,33}

In the 4-halo-1-naphthoyl indole series (Table 1), CB₁ affinity was consistently and substantially better for each 1-pentyl-3-(1-naphthoyl)indole than for the corresponding 1-propyl compound. For example, the K_i value for JWH-412, 1-pentyl-3-(4-fluoro-1-naphthoyl)indole, was 7.2 nM compared to a K_i of 240 nM for JWH-414, 1-propyl-3-(4-fluoro-1-naphthoyl)indole. CB₁ affinities of the 1-propyl-3-(4-halo-1-naphthoyl)indoles were moderate, ranging from 93 to 240 nM, while the 1-pentyl-3-(4-halo-1-naphthoyl)indoles had good affinities, ranging from 1.2 to 7.2 nM. A similar pattern of differential affinities as a function of the length of the alkyl substituent was observed for the 1-alkyl-2-methyl-3-(4-halo-1-naphthoyl)indole series; however, the presence of a 2-methyl substituent substantially decreased CB₁ affinities for compounds with either alkyl length. While the resulting CB₁ affinities for the 1-propyl analogs were moderate to poor, with K_is ranging from 187 to 530 nM, the 1-pentyl compounds retained good CB₁ affinity, with K_i

values ranging from 8.9 to 14 nM. Electronegativity of the 4-halogen substituent also affected CB₁ affinity. 4-Chloro substitution produced the best CB₁ affinity in each group, K_i = 93 nM for JWH-400, 1-propyl-3-(4-chloro-1-naphthoyl)indole; K_i = 187 nM for JWH-399, 1-propyl-2-methyl-3-(4-chloro-1-naphthoyl)indole; K_i = 8.9 nM for JWH-397, 1-pentyl-2-methyl-3-(4-chloro-1-naphthoyl)indole, except for the 1-pentyl-3-(4-halo-1-naphthoyl)indoles, in which 3-(4-bromo-1-naphthoyl) substitution resulted in optimal CB₁ affinity (K_i = 1.2 for JWH-387). Increasing electronegativity through substitution of a 3-(4-fluoro-1-naphthoyl) substituent greatly lessened CB₁ affinity, K_i = 240 nM for JWH-414, 1-propyl-3-(4-fluoro-1-naphthoyl)indole; K_i = 7.2 nM for JWH-412, 1-pentyl-3-(4-fluoro-1-naphthoyl)indole; K_i = 530 nM for JWH-415, 1-propyl-2-methyl-3-(4-fluoro-1-naphthoyl)indole and K_i = 14 nM for JWH-413, 1-pentyl-2-methyl-3-(4-fluoro-1-naphthoyl)indole. Substitution of a less electronegative iodo substituent in 1-propyl-2-methyl-3-(4-iodo-1-naphthoyl)indole, JWH-422 (K_i = 501 nM) has a similar effect. For the other 1-propyl-3-(4-halo-1-naphthoyl)indoles, 1-pentyl-3-(4-halo-1-naphthoyl)indoles, and 1-pentyl-2-methyl-3-(4-halo-1-naphthoyl)indoles, the CB₁ receptor affinities for 3-(4-chloro, bromo, iodo-1-naphthoyl) indoles do not vary widely within each series.

Regardless of their CB₁ affinities, all of the 3-(4-halo-1-naphthoyl)indoles have good CB₂ affinities. Further, whereas THC shows similar affinities for both CB₁ and CB₂ receptors, WIN-55,212-2 and the majority of the 3-(4-halo-1-naphthoyl)indoles [except for two, JWH-398 and JWH-387, 1-pentyl-3-(4-chloro-1-naphthoyl)indole and 1-pentyl-3-(4-bromo-1-naphthoyl)indole, respectively] are mildly to moderately CB₂ selective, with CB₁/CB₂ ratios ranging from 2 to 25. The 1-propyl analogs exhibit better CB₂ selectivity than corresponding 1-pentyl compounds regardless of whether they have a methyl substitution at the indole 2-position or are unsubstituted. However, compared to the analogs that are unsubstituted at the 2-position of the indole group, CB₂ selectivity (but not absolute affinity) is increased with addition of the 2-methyl substituent for either the 1-propyl or 1-pentyl indoles. The best absolute values for CB₂ affinities are exhibited by 1-pentyl-3-(4-halo-1-naphthoyl)indoles, a pattern that was also observed for CB₁ affinities. For the 1-pentyl-3-(4-halo-1-naphthoyl)indole series, CB₂ affinities ranged from 1.1 to 13 nM, with the best affinity obtained for JWH-387, 1-pentyl-3-(4-bromo-1-naphthoyl)indole. Decreasing electronegativity by substitution of a 4-iodo-1-naphthoyl group correspondingly decreases CB₂ affinity (JWH-421, K_i = 13 nM). Although increasing electronegativity by 4-chloro-1-naphthoyl or 4-fluoro-1-naphthoyl substitution also decreases CB₂ affinity, the magnitude of these decreases is much less [K_i = 2.8 nM for JWH-398, 1-pentyl-3-(4-chloro-1-naphthoyl)indole and K_i = 3.2 nM for JWH-412, 1-pentyl-2-H-3-(4-fluoro-1-naphthoyl)indole]. CB₂ affinities for the 1-pentyl-2-methyl-3-(4-halo-1-naphthoyl)indole series vary little across 4-halogen substitutions, ranging from 2.1 to 2.8 nM. In contrast, CB₂ affinities for the 1-propyl-3-(4-halo-1-naphthoyl)indoles range from 6.6 nM for 1-propyl-3-(4-iodo-1-naphthoyl)indole, JWH-423, to 44 nM for 1-propyl-2-H-3-(4-chloro-1-naphthoyl)indole, JWH-400. The remaining 1-propyl indoles possess CB₂ affinities that are similar (20 - 33 nM).

Because limited yields prevented determination of full dose-effect curves, assessment of in vivo potency was not possible for many of the 4-halo-1-naphthoyl indoles; however, tests with probe doses (3 to 30 mg/kg) suggested that compounds with good to moderate CB₁ affinity exhibit cannabinoid activity in the in vivo test battery. Where potency calculations were possible, compounds with good CB₁ affinities also possess good potencies in each of the four in vivo tests, with one exception. JWH-415, 1-propyl-2-methyl-3-(4-fluoro-1-naphthoyl)indole, has poor CB₁ affinity (K_i = 530 nM); yet, it produces all characteristic cannabinoid effects, albeit potencies are lower compared to other compounds with better CB₁ affinities. Further, 3 mg/kg rimonabant blocked or partially blocked all tetrad effects of 30 mg/kg JWH-415, suggesting that these effects were CB₁ receptor-mediated. To evaluate

possible receptor mediation of the in vivo effects of JWH-415, the compound was assessed in a [^{35}S]GTP γ S assay to determine its ability to activate the CB₁ receptor. JWH-415 produces G-protein activation in a concentration-dependent manner, with an EC₅₀ of 268 μM (± 42 sem). Efficacy, however, is only partial ($E_{\text{max}} = 59\% \pm 3$).

Table 2 presents a summary of the pharmacological results for the 1-alkyl-3-(8-halo-1-naphthoyl)indoles. All of these compounds possess substantially less affinity for both CB₁ and CB₂ receptors than did the comparable 1-alkyl-3-(4-halo-1-naphthoyl)indoles, albeit some of the SAR patterns that were observed in the 4-halogen series are also observed in the 8-halogen series. First, the 1-pentyl-3-(8-halo-1-naphthoyl)indoles exhibit better CB₁ and CB₂ affinities than the 1-propyl-3-(8-halo-1-naphthoyl)indoles. The best CB₁ affinity for the 1-propyl series is a K_i of 642 nM for JWH-456, 1-propyl-3-(8-chloro-1-naphthoyl)indole. Several of the compounds fail to demonstrate measurable binding to the CB₁ receptor [$K_i > 10,000$ for JWH-428, 1-propyl-3-(8-bromo-1-naphthoyl)indole, JWH-461, 1-propyl-2-methyl-3-(8-chloro-1-naphthoyl)indole, and JWH-429, 1-propyl-2-methyl-3-(8-bromo-1-naphthoyl)indole]. In contrast, CB₁ affinities for the 1-pentyl-3-(8-halo-1-naphthoyl)indoles range from 21 to 73 nM and 54 to 522 nM for the 1-pentyl-2-methyl-3-(8-halo-1-naphthoyl)indole series. CB₂ affinities are also better for the 1-pentyl-3-(8-halo-1-naphthoyl)indoles than for the 1-propyl-3-(8-halo-1-naphthoyl)indoles, ranging from $K_i = 3.3$ to 10 nM for the 1-pentyl-3-(8-halo-1-naphthoyl)indoles and $K_i = 10$ to 19 nM for the 1-pentyl-2-methyl-3-(8-halo-1-naphthoyl)indoles. For the propyl analogs, CB₂ affinities range from 102 to 152 nM for the 1-propyl-3-(8-halo-1-naphthoyl)indoles and from 174 to 536 nM for the 1-propyl-2-methyl-3-(8-halo-1-naphthoyl)indoles. As was the case for the compounds with 4-halo-1-naphthoyl substitutions, all compounds are CB₂ selective. In addition, methylation at the 2-position of the indole group results in decreased CB₁ affinities, as it did for the 4-halogen series. In the 1-pentyl-3-(8-halo-1-naphthoyl) series, a moderate degree of electronegativity appears to optimize CB₁ affinity, with the caveat that synthesis of the highly negative 1-alkyl-3-(8-fluoro-1-naphthoyl)indoles was impractical. Hence, JWH-457, 1-pentyl-3-(8-chloro-1-naphthoyl)indole, JWH-424, 1-pentyl-3-(8-bromo-1-naphthoyl)indole and JWH-425, 1-pentyl-2-methyl-3-(8-bromo-1-naphthoyl)indole, have the best CB₁ affinities, with $K_i = 23$, 21 and 54 nM, respectively. JWH-425 also has the best CB₂ affinity of the 1-pentyl-2-methyl-3-(8-halo-1-naphthoyl)indoles, with $K_i = 10$ nM, whereas the best CB₂ affinity of the 1-pentyl-3-(8-halo-1-naphthoyl)indoles is JWH-416, 1-pentyl-3-(8-iodo-1-naphthoyl)indole, with $K_i = 3.3$ nM. The only compound that produced the full cannabinoid profile in vivo was JWH-424, 1-pentyl-3-(8-bromo-1-naphthoyl)indole. JWH-457, 1-pentyl-3-(8-chloro-1-naphthoyl)indole, which also has good CB₁ receptor affinity ($K_i = 23$ nM) is much less potent in vivo than would be expected on the basis of its CB₁ affinity.

3. Discussion

The primary purpose of this study was to examine steric and electronic effects on CB₁ and CB₂ receptor affinities and in vivo pharmacology of moderately electron withdrawing halogen substituents at the naphthoyl C-4 or C-8 positions in a series of 1-alkyl-3-(1-naphthoyl)indoles. In addition, two electroneutral structural features (the length of the *N*-alkyl group and the presence of a methyl at the 2-indole position) were manipulated and were found to strongly affect affinities at both cannabinoid receptors for this series of compounds. 1-Pentyl-3-(1-naphthoyl)indoles consistently exhibit more favorable CB₁ affinity than 1-propyl-3-(1-naphthoyl)indoles with the corresponding C-4 or C-8 substitutions. Whereas CB₁ affinities range from good for 1-pentyl-3-(1-naphthoyl)indoles with C-4 substitutions (1.2 to 14 nM) to moderate or poor for those with C-8 substitutions (21 to 522 nM), CB₁ affinities for 1-propyl-3-(1-naphthoyl)indoles are moderate or poor (93 to 530 nM) for C-4 substitutions and are consistently poor or negligible for propyl

compounds with C-8 substitutions. Absolute values obtained for CB₂ affinity are also better for 1-pentyl-3-(1-naphthoyl)indoles both those with C-4 and C-8 substituents, ranging from 1.1 nM for 1-pentyl-3-(4-bromo-1-naphthoyl)indole (JWH-387) to 19 nM for 1-pentyl-2-methyl-3-(8-chloro-1-naphthoyl)indole (JWH-462). However, the combination of the decrease in CB₁ affinities provided by a 1-propyl group combined with relatively little decrease in CB₂ affinity leads to greater CB₂ selectivity for the 1-propyl-3-(1-naphthoyl)indoles than for those indoles with an *N*-pentyl group. Greater CB₂ selectivity appears to be a function of the length of the N-alkyl group, as similar selectivity for CB₂ receptors was found for JWH-015 (**5**), a 1-propyl-3-(1-naphthoyl)indole derivative that is unsubstituted on the naphthoyl moiety.^{15,19} In addition to the length of the alkyl group, the presence of a methyl at the indole 2-position also affects CB₁ affinity. In the compounds with C-4 substitutions, the presence of a 2-methyl substituent decreases CB₁ affinity without having substantive effect on CB₂ affinity; hence, the net result of this substitution is increased CB₂ selectivity. In contrast, 2-methyl substitution in the series of compounds with C-8 substitutions decreases CB₂ affinity in the set of 1-propyl analogs, and to a lesser extent, in the set of 1-pentyl analogs, with the most pronounced decrease seen for 1-propyl-2-methyl-3-(8-iodo-1-naphthoyl)indole (JWH-418). In summary, the results observed with the two electroneutral structural manipulations are consistent with a number of previous SAR investigations of indole- and pyrrole-derived cannabinoids in which these structural manipulations produce similar patterns of alterations of CB₁ and CB₂ affinities and selectivity and suggest that length of the alkyl substituent is as crucial for this cannabinoid structural motif as it is for cannabinoids based on the tetrahydrocannabinol structural motif.^{2,19,21}

The *in vivo* evaluation of the series of naphthoylindoles with C-4 and C-8, that was undertaken for those compounds for which sufficient sample was available, revealed that efficacy for producing cannabimimetic effects in mice is associated with good CB₁ affinity, as has been shown previously for structural analogs based on a tetrahydrocannabinol template as well as for other indole and pyrrole cannabinoid series.^{18,34} One anomaly in the current series was JWH-415, 1-propyl-2-methyl-3-(4-fluoro-naphthoyl)indole. Although the CB₁ affinity of JWH-415 is poor ($K_i = 530$ nM), it exhibited rimonabant-reversible activity in the battery of mouse tests. Further investigation showed that JWH-415 is a low efficacy agonist at the CB₁ receptor. A similar finding was reported previously for several 1-deoxy-THC analogs, with the most prominent being deoxy- $\Delta^{9(11)}$ -THC-dimethylheptyl (JWH-104). Similar to the results observed here with JWH-415, JWH-104 has low CB₁ affinity ($K_i = 909$ nM); yet, it produced cannabimimetic effects in the battery of mouse tests that were blocked by rimonabant.³⁵ Results of a [³⁵S]GTP γ S binding assay showed that JWH-104 also functions as a low efficacy agonist at CB₁ receptors. Interestingly, JWH-104 did not substitute for THC in a drug discrimination procedure in mice (an animal model of marijuana-like intoxication),^{36,37} suggesting that it does not produce the entire complement of cannabinoid effects seen with THC. JWH-415 has not been tested in the latter behavioral test.

To date, the only substituents on the naphthoyl moiety that had been examined in indole-derived cannabinoids were weakly to moderately electron releasing. In the present study, moderately electron withdrawing C-4 naphthoyl substituents with a range of electronegativity (F, Cl, Br, and I) were synthesized and evaluated. Results show that moderate electronegativity is favorable for CB₁ affinity, with chloro analogs having the best, but modest, affinity in the series of 1-propyl analogs (JWH-400 and JWH-399) and 1-pentyl-2-methyl analogs (JWH-397). The 4-bromonaphthoyl analog (JWH-387) has the best affinity of the 1-pentyl analogs that are unsubstituted at C-2 of the indole. Fluorine is the most electronegative of the halogens and a C-4 fluoro substituent suppresses CB₁ affinity in the 1-propyl analogs, with or without a 2-methyl substituent on the indole core (JWH-415 and

JWH-414, respectively). The least electronegative halogen is iodine and an iodo substituent at C-4 also reduces CB₁ affinity somewhat for the 1-propyl-2-methyl analog, JWH-422. However, the other 4-iodonaphthoyl compounds have CB₁ receptor affinities that are similar to those of the chloro and bromo analogs. Previous work has shown that 4-fluorobenzyl moiety in place of the naphthoyl substituent in a series of 1-pentyl-phenylacetylindoles²³ or for the hydroxy group of THC in a series of fluorinated classical cannabinoid analogs³⁸ substantially decreases CB₁ receptor affinity and in vivo potency. CB₂ affinity is less affected by electronegativity, particularly in the 1-pentyl and 1-pentyl-2-methyl series where CB₂ affinities are uniformly good and range from 1.1 to 3.2 nM.

In the series of 3-(8-halo-1-naphthoyl)indoles, iodine, the least electronegative halogen, decreases CB₁ affinity in the 1-pentyl analogs, both those with and without a methyl group at the 2-position of the indole (JWH-417 and JWH-416, respectively). The CB₁ receptor affinities for the 1-propyl analogs with halogen substituents C-8 are from negligible to very low across the entire range of negativities evaluated (i.e., Cl, Br, and I).

In addition to electronic effects, it is likely that steric effects of the C-8 substitutions contribute to the low CB₁ affinities and CB₂ selectivity of this series of compounds. In earlier work it was found that 1-propyl- and 1-pentyl-2-methyl-3-(2-methoxy-1-naphthoyl)indoles (**13**) have restricted rotation about the naphthalene C-1 bond to the carbonyl carbon.²⁰ In addition, two of the compounds in this series were very selective for the CB₂ receptor. While molecular modeling studies of the 3-(8-halogenated-1-naphthoyl)indole derivatives were not carried out, their consistently lower CB₁ affinity (compared to compounds with corresponding C-4 substitutions) suggests that steric hinderance of rotation caused by the C-8 substitution interferes with interaction with the CB₁ receptor, particularly for those compounds with an indole C-2 methyl substituent. The ¹H NMR spectra of these compounds is in agreement with this hypothesis, see above and the experimental section.³⁰ This is particularly apparent with a relatively large iodo substituent at C-8 of the naphthoyl moiety. A possible mechanism for the decrease in CB₁ affinity is that substitution at C-8 of the naphthoyl ring prevents optimal aromatic stacking of these compounds with the aromatic amino acids of the CB₁ receptor. These interactions have been shown to be important for the binding of cannabimimetic indoles to the CB₁ receptor.^{20,39} Similar positional biases also occurred in series of 1-pentyl-3-phenylacetylindoles and 1-alkyl-2-aryl-4-(1-naphthoyl)pyrroles with electron withdrawing substituents.^{23,40} With all substituents CB₁ and CB₂ affinities were best with substitution at the 2-position of the phenyl or pyrrole moieties, with intermediate affinities for the 3-position and with the least affinity for compounds with 4-substituents, suggesting that positional substitutions following conversion of the indole template to a pyrrole produce similar changes in affinities as deletion of one of the naphthoyl rings (i.e., conversion to a phenylacetyl) with the same positional substitutions on the opposite side of the molecule. Hence, the position of substituents on either side of the molecule appears to be important for CB₁ receptor affinity and in vivo potency for indole-derived cannabinoids, as it has been shown to be for synthetic cannabinoids based upon a THC structural template.⁴¹ For example, compounds with halogen (e.g., iodo, bromo, fluoro) or nitrogen substitutions at the C-2 and 4-aryl positions (on either side of the C-3 pentyl side chain of THC) had lower CB₁ receptor affinity and were less potent in vivo than compounds with similar substitutions at the terminal end of the side chain.⁴² In addition, the number of aromatic constituents also may play a role in interaction with the CB₁ receptor, as suggested by the finding that the series of 1-pentyl-3-phenylacetylindoles shows attenuated CB₁ receptor affinity compared to their 1-pentyl-3-naphthoylindole congeners.²⁰

4. Conclusions

The major structural manipulations in the present series included halogen substitution on the 3-naphthoyl group (i.e., fluoro, chloro, bromo, and iodo), the position of the substituent on the naphthoyl (i.e., C-4 or C-8), length of the *N*-alkyl group (i.e., propyl or pentyl), and presence of a methyl group at the 2-position of the indole nucleus. Of these factors, the position of the halogen substituent on the naphthoyl group and the length of the *N*-alkyl group were the most critical factors affecting CB₁ and CB₂ affinities, with C-4 and 1-pentyl substitutions, respectively, producing consistently good affinities at both receptors. While CB₂ selectivity was enhanced by 1-propyl (versus 1-pentyl) substitution, this effect occurred primarily because of a corresponding decrease in CB₁ affinity rather than an improvement in CB₂ affinity. Together, these results suggest that steric effects play a far more prominent role in determining the nature of the interaction of this series of 1-alkyl-3-(1-naphthoyl)indoles with the identified cannabinoid receptors than do electronic effects.

5. Experimental

5.1. General

¹H and ¹³C NMR spectra were recorded on a Bruker 300AC spectrometer or a 500 MHz Bruker Fourier Transform Spectrometer. Mass spectral analyses were performed on a Hewlett-Packard 5890A capillary gas chromatograph equipped with a mass sensitive detector or a Shimadzu QP2010 capillary gas chromatograph/mass spectrometer. HRMS data were obtained in the Mass Spectrometry Laboratory, School of Chemical Sciences, University of Illinois. Ether and THF were distilled from Na-benzophenone ketyl immediately before use, and other solvents were purified using standard procedures. Column chromatography was carried out on Sorbent Technologies silica gel (32 - 63 μ) using the indicated solvents as eluents. All new compounds were homogeneous to TLC and ¹³C NMR. All target compounds were homogeneous to GLC or TLC in two different solvent systems. TLC was carried out using 200 μm silica gel plates using the indicated solvents. GLC analyses were performed on the Hewlett-Packard 5890A GC/MS or the Shimadzu QP2010 using a 60 m carbowax column and helium gas as a carrier. An initial column temperature of 60 °C was employed and the temperature was increased at a rate of 1.5 °C/min to a maximum temperature of 300 °C with a total run time of 20 min.

5.1.1. 1-Propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414, 9, R = C₃H₇, R' = H, X = F)—To a solution of 0.07 g (0.44 mmol) of 1-propylindole in 5 mL of dry dichloromethane under Ar was added 0.60 mL (0.60 mmol), of 1M dimethylaluminum chloride in hexanes and the mixture was stirred for 30 min at 0 °C. To this mixture was added dropwise a solution of freshly prepared 4-fluoro-1-naphthoyl chloride in 3 mL of dry dichloromethane. The acid chloride was prepared by the addition of 3 mL (41 mmol) of thionyl chloride to 0.12g (0.63 mmol) of 4-fluoro-1-naphthoic acid under Ar. The mixture was heated at reflux for 2 h, cooled to ambient temperature and the thionyl chloride was removed *in vacuo*. The acid chloride was added to the indole mixture without further purification and the mixture was stirred at ambient temperature overnight. The reaction was quenched with water and extracted with ether. The ethereal solution was washed with water and 1 M KOH, dried (MgSO₄) and the solvent was removed *in vacuo* to give the crude product, which was purified by column chromatography (petroleum ether:ether, 8:2) to give 0.076 g (52%) of 1-propyl-3-(4-fluoro-1-naphthoyl)indole as a tan solid: m.p. 166-167 °C; ¹H NMR (500 MHz, CDCl₃) δ 0.94 (t, *J*=7.3 Hz, 3H), 1.87 (sextet, *J*= 7.3 Hz, 2H), 4.09 (t, *J*= 7 Hz, 2H), 7.21 (t, *J*=8.8 Hz, 1H), 7.40-7.43 (m, 4H), 7.57 (t, *J*= 7Hz, 1H), 7.62 (t, *J*= 7 Hz, 1H), 7.66 (t, *J*= 6.5 Hz, 1H), 8.22 (d, *J*= 8 Hz, 1H), 8.29 (d, *J*= 8 Hz, 1H), 8.51-8.53 (m, 1H); ¹³C NMR (125.77 MHz, CDCl₃) δ 11.3, 23.1, 48.8, 108.1, 108.3, 110.1,

117.5, 120.7, 120.7, 122.9, 122.9, 123.7, 126.0, 126.4, 126.4, 126.7, 127.0, 127.8, 137.1, 137.8, 191.1; GC/MS (EI) m/z (rel intensity) 331 (100), 302 (66), 274 (12), 186 (95), 144 (47); HRMS (ES⁺) m/z calcd for C₂₂H₁₈FNO: 331.1372; found: 331.1367.

5.1.2. 2-Methyl-1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-415, 9, R = C₃H₇, R' = CH₃, X = F)—JWH-415 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.08 g (0.45 mmol) of 2-methyl-1-propylindole and 0.13 g (0.68 mmol) of 4-fluoro-1-naphthoic acid there was obtained after column chromatography (petroleum ether: ether, 8:2) 0.089 g (56%) of 2-methyl-1-propyl-3-(4-fluoro-1-naphthoyl)indole as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 0.98 (t, J = 7.5 Hz, 3H), 1.82 (sextet, J = 7.5 Hz, 2H), 2.51 (s, 3H), 4.09 (t, J = 7.5 Hz, 2H), 6.99 (t, J = 7.5 Hz, 1H), 7.16 (q, J = 8.3 Hz, 3H), 7.31 (d, J = 8.3 Hz, 1H), 7.50 (t, J = 7.4 Hz, 1H), 7.53–7.56 (m, 2H), 8.17–8.20 (m, 2H); ¹³C NMR (125.77 MHz, CDCl₃) δ 11.5, 12.6, 23.0, 44.9, 108.7, 108.8, 109.6, 114.9, 120.7, 120.8, 121.1, 121.9, 122.3, 125.7, 126.7, 126.7, 127.1, 127.9, 136.1, 136.5, 145.6, 190.5; GC/MS (EI) m/z (rel intensity) 345 (100), 328 (34), 288 (47), 173 (73); HRMS (ES⁺) m/z calcd for C₂₃H₂₀FNO: 345.1529; found: 345.1531

5.1.3. 1-Pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412, 9, R = C₅H₁₁, R' = H, X = F)—JWH-412 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.070 g (0.38 mmol) of 1-pentylindole and 0.11 g (0.58 mmol) of 4-fluoro-1-naphthoic acid there was obtained after chromatography (petroleum ether: ether, 7:3) 0.021 g (10%) of 1-pentyl-3-(4-fluoro-1-naphthoyl)indole as a brown oil: ¹H NMR (500 MHz, CDCl₃) δ 0.89 (t, J = 7 Hz, 3H), 1.28–1.35 (m, 4H), 1.85 (p, J = 7 Hz, 2H), 4.11 (t, J = 7 Hz, 2H), 7.22 (dd, J = 8, 10 Hz, 1H), 7.38–7.40 (m, 3H), 7.42–7.43 (m, 1H), 7.56 (t, J = 7 Hz, 1H), 7.61 (t, J = 7 Hz, 1H), 7.66 (dd, J = 5.5, 8 Hz, 1H), 8.21 (d, J = 8 Hz, 1H), 8.28 (d, J = 8.5 Hz, 1H), 8.48–8.50 (m, 1H); ¹³C NMR (125.77 MHz, CDCl₃) δ 13.9, 22.2, 28.9, 29.5, 47.2, 108.1, 108.3, 110.0, 117.5, 120.6, 120.7, 122.9, 122.9, 123.7, 126.0, 126.4, 126.7, 127.0, 127.8, 132.6, 137.1, 137.7, 191.0; GC/MS (EI) m/z (rel intensity) 359 (50), 343 (22), 302 (54), 281 (26), 207 (100); HRMS (ES⁺) m/z calcd for C₂₄H₂₂FNO: 359.1685; found: 359.1679

5.1.4. 2-Methyl-1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-413, 9, R = C₅H₁₁, R' = CH₃, X = F)—JWH-413 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.10 g (0.48 mmol) of 2-methyl-1-pentylindole and 0.14 g (0.74 mmol) of 4-fluoro-1-naphthoic acid there was obtained after column chromatography (petroleum ether: ether, 9:1) 0.022 g (12%) of 2-methyl-1-pentyl-3-(4-fluoro-1-naphthoyl)indole as a green oil: ¹H NMR (500 MHz, CDCl₃) δ 0.95 (t, J = 7 Hz, 3H), 1.41–1.42 (m, 4H), 1.81–1.85 (m, 2H), 2.56 (s, 3H), 4.16 (t, J = 7.5 Hz, 2H), 7.03 (d, J = 8 Hz, 1H), 7.15–7.22 (m, 4H), 7.34 (d, J = 8.5 Hz, 1H), 7.54–7.60 (m, 3H), 8.22 (d, J = 9 Hz, 1H); ¹³C NMR (125.77 MHz, CDCl₃) δ 12.6, 13.9, 22.4, 29.1, 29.4, 43.4, 108.6, 108.8, 109.5, 114.9, 120.7, 120.7, 121.1, 121.9, 122.2, 123.9, 124.1, 125.7, 126.6, 126.7, 127.1, 127.9, 136.1, 145.5, 192.4; GC/MS (EI) m/z (rel intensity) 373 (74), 358 (45), 316 (44), 173 (100), 145 (55); HRMS (ES⁺) m/z calcd for C₂₅H₂₄FNO: 373.1842; found: 373.1850.

5.1.5. 1-Acetyl-4-chloro-naphthalene (24, X = Cl)—To a solution of 0.15 g (1.9 mmol) of acetyl chloride in 8 mL of freshly distilled dichloromethane under N₂ was added 0.26 g (2.0 mmol) of AlCl₃. This mixture was stirred at ambient temperature for 5 min and 0.28 g (1.72 mmol) of 1-chloronaphthalene was added dropwise over 10 min. The mixture was heated to 40 °C and stirred for 1 h, poured over a mixture of ice and concentrated HCl. The product was extracted into ether, washed with brine and dried (MgSO₄). The solution

was concentrated *in vacuo* to give 0.56 g (84%) of 1-acetyl-4-chloro-naphthalene as a yellow oil, which was used without further purification: ^1H NMR (300 MHz, CDCl_3) δ 2.58 (s, 3 H), 7.33 (d, $J = 7.8$ Hz, 1 H), 7.48-7.55 (m, 2 H), 7.57 (d, $J = 7.8$ Hz, 1 H), 8.16 (d, $J = 7.8$, 1 H), 8.72 (d, $J = 7.2$, 1 H); ^{13}C NMR (75.5 MHz, CDCl_3) δ 29.8, 124.5, 124.7, 126.4, 127.4, 128.4, 128.6, 130.9, 131.2, 134.1, 136.6, 200.5; GC/MS (EI) m/z (rel intensity) 204 (69), 189 (100), 161 (75), 126 (54). The data agree in all respects with those reported previously.⁴³

5.1.6. 4-Chloro-1-naphthoic acid (22, X = Cl)—To a solution of 2.44 g (11.9 mmol) of 1-acetyl-4-chloronaphthalene in 5 mL of freshly distilled pyridine under N_2 was added 3.33 g (13.1 mmol) of I_2 dissolved in 15 mL of freshly distilled pyridine. The mixture was heated at reflux for 40 min, cooled to ambient temperature and diluted with ether until a brown precipitate formed. The precipitate was filtered off, suspended in 12 mL of 6M aqueous NaOH and heated at reflux for 2 h. After cooling the solution was acidified with 10% HCl, the crude 4-chloro-1-naphthoic acid was extracted into ether and the ethereal extract was washed with brine. After drying (MgSO_4) the solution was concentrated *in vacuo*. The product was dissolved in 25 mL of MeOH to which 5 mL of concentrated H_2SO_4 was cautiously added. The solution was heated at reflux for 3 h. After cooling to ambient temperature the crude ester was extracted into ether, the ethereal solution was washed with brine and dried (MgSO_4). The solution was concentrated *in vacuo* to give 1.66 g (63%) of methyl 4-chloro-1-naphthoate as a brown oil, which was used without further purification: ^1H NMR (300 MHz, CDCl_3) δ 3.90 (s, 3 H), 7.38 (d, $J = 7.8$, 1 H), 7.45-7.56 (m, 2H), 7.87 (d, $J = 8.1$, 1 H), 8.18 (d, $J = 8.4$, 1 H), 8.93 (d, $J = 8.1$, 1 H); ^{13}C NMR (75.5 MHz, CDCl_3) δ 52.1, 124.6, 124.9, 125.8, 126.2, 127.1, 128.3, 129.9, 130.7, 132.3, 137.2, 166.9; GC/MS (EI) m/z (rel intensity) 220 (61), 189 (100), 161 (48), 126 (42).

A mixture of 0.25 g (1.1 mmol) of methyl 4-chloro-1-naphthoate and 2.10 g (37.4 mmol) of KOH in 20 mL of H_2O was heated at reflux for 12 h under N_2 . The reaction mixture was cooled to ambient temperature, acidified with concentrated HCl and the product was extracted into ether and dried (MgSO_4). The organic phase was concentrated *in vacuo* to give 0.27 g (88%) of 4-chloro-1-naphthoic acid as an off-white solid: m.p. 223-224 °C (lit m.p. 220-221 °C⁴⁴); ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.74-7.81 (m, 3H), 8.11 (d, $J = 6$ Hz, 1H), 8.28-8.31 (m, 1H), 8.93-8.97 (m, 1H), 13.8 (br s, 1H); ^{13}C NMR (75.5 MHz, $\text{DMSO}-d_6$) δ 124.7, 126.1, 126.7, 127.9, 128.3, 129.0, 130.4, 130.6, 132.3, 135.7, 168.5.

5.1.7. 3-(4-Chloro-1-naphthoyl)indole (18, R = H, Ar = 4-chloronaphthyl)—A solution of 0.48 mL (1.45 mmol) of EtMgBr [3.0M in diethyl ether] was added with stirring to 3 mL of dry ether at 0 °C under Ar and stirred until it became cloudy white. A solution of 0.12 g (1.06 mmol) of indole in 2 mL of dry ether was added and the mixture was stirred at 0 °C for 30 min followed by stirring at ambient temperature for 30 min. A solution of freshly prepared 4-chloro-1-naphthoyl chloride in 3 mL of dry ether was added dropwise via syringe. The acid chloride was prepared by the addition of 3 mL (41 mmol) of thionyl chloride to 0.20 g (0.97 mmol) of chloro-1-naphthoic acid under Ar. The mixture was heated at reflux for 2 h, cooled to ambient temperature, and the thionyl chloride was removed *in vacuo* to give the acid chloride, which was added to the indole mixture without further purification. The acid chloride and indole mixture was stirred at ambient temperature for 4 h, quenched with NH_4Cl and extracted with ether. The ethereal solution was allowed to stand at ambient temperature for 20 min upon which time a precipitate was filtered out to give 0.11 g (38%) of 3-(4-chloro-1-naphthoyl)indole as a cream colored solid: ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.27-7.31 (m, 2H), 7.52-7.55 (m, 1H), 7.61-7.71 (m, 2H), 7.74-7.76 (m, 2H), 7.80 (d, $J = 7.8$ Hz, 1H), 8.08 (d, $J = 8.1$ Hz, 1H), 8.29-8.33 (m, 2H), 12.25 (br s, 1H); ^{13}C NMR (75.5 MHz, $\text{DMSO}-d_6$) δ 112.9, 117.5, 121.9, 122.8, 123.8, 124.5, 126.0, 126.3, 126.6, 128.2, 128.4, 130.5, 131.8, 132.5, 137.5, 137.7, 138.7, 190.8.

5.1.8. 1-Propyl-3-(4-chloro-1-naphthoyl)indole (JWH-400, 10, R = C₃H₇, R' = H, X = Cl)—A. A solution of 0.16 g (0.52 mmol) of 3-(4-chloro-1-naphthoyl)indole and 0.13 g (2.35 mmol) of crushed KOH in 5 mL of DMSO was stirred at ambient temperature for 1 h. To this mixture was added 0.14 g (0.94 mmol) of **18** and 0.18 g (1.05 mmol) of 1-iodopropane. Stirring at ambient temperature was continued for 6 h. The reaction was quenched with H₂O and the product was extracted with ethyl acetate. After being dried (MgSO₄) and concentrated *in vacuo* the product was purified by column chromatography (petroleum ether: ethyl acetate, 7:3) to give 0.03 g (15%) of JWH-400 as a tan solid: m.p. 194–195 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 6.79 (t, *J* = 7.3 Hz, 3H), 1.73 (sextet, *J* = 7.3 Hz, 2H), 4.17 (t, *J* = 7.0 Hz, 2H), 7.33–7.36 (m, 2H), 7.63–7.69 (m, 3H), 7.76 (t, *J* = 7.5 Hz, 1H), 7.83–8.84 (m, 2H), 8.07 (d, *J* = 8.0 Hz, 1H), 8.33 (t, *J* = 8.5 Hz, 2H); ¹³C NMR (125.77 MHz, DMSO-*d*₆) δ 11.4, 23.2, 48.2, 111.6, 116.4, 122.2, 123.1, 123.9, 124.5, 126.1, 126.3, 126.5, 126.8, 128.3, 128.4, 130.6, 131.8, 132.5, 137.4, 138.7, 140.4, 190.4; GC/MS (EI) *m/z* (rel intensity) 347 (96), 330 (41), 318 (54), 186 (100); HRMS (EI⁺) calcd for C₂₂H₁₈ClNO: 347.1077; found: 347.0927.

B. JWH-400 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.13 g (0.80 mmol) of 1-propylindole and 0.15 g (0.73 mmol) of 4-chloro-1-naphthoic acid there was obtained after chromatography (petroleum ether: ethyl acetate, 7:3) 0.04 g (15%) of 1-propyl-3-(4-bromo-1-naphthoyl)indole (JWH-400) as a tan solid: m.p. 194–195 °C. The spectroscopic properties were identical to those of material prepared by method A.

5.1.9. 2-Methyl-3-(4-chloro-1-naphthoyl)indole (18, R = CH₃, Ar = 4-chloronaphthyl)—Indole 18 (Ar = 4-chloronaphthyl) was prepared using the procedure employed for the synthesis of 3-(4-chloro-1-naphthoyl)indole. From 0.08 g (0.64 mmol) of 2-methylindole and 4-chloro-1-naphthoyl chloride prepared from 0.12 g (0.58 mmol) of 4-chloro-1-naphthoic acid with 0.29 mL (0.87 mmol) of EtMgBr (3.0M in diethyl ether) there was obtained 0.12 g (62%) of 2-methyl-3-(4-chloro-1-naphthoyl)indole as a cream colored solid: ¹H NMR (300 MHz, DMSO-*d*₆) δ 6.95 (t, *J* = 7.2 Hz, 1H), 7.08 (t, *J* = 7.5 Hz, 1H), 7.26 (d, *J* = 7.5 Hz, 1H), 7.39 (d, *J* = 7.8 Hz, 1H), 7.46–7.69 (m, 5H), 7.76 (d, *J* = 7.5 Hz, 2H), 7.87 (d, *J* = 8.4 Hz, 1H), 8.25 (d, *J* = 8.4 Hz, 1H), 11.1 (br s, 1H); ¹³C NMR (75.5 MHz, DMSO-*d*₆) δ 14.7, 112.0, 114.0, 120.5, 122.0, 122.6, 124.5, 125.1, 126.0, 126.5, 127.4, 128.3, 128.4, 130.5, 131.2, 132.1, 135.5, 140.7, 146.7, 191.3.

5.1.10. 2-Methyl-1-propyl-3-(4-chloro-1-naphthoyl)indole (JWH-399, 10, R = C₃H₇, R' = CH₃, X = Cl)—JWH-399 was prepared by procedure A employed for the synthesis of JWH-400. From 0.12 g (0.37 mmol) of 2-methyl-3-(4-chloro-1-naphthoyl)indole, 0.09 g (1.69 mmol) of crushed KOH and 0.13 g (0.75 mmol) of 1-iodopropane there was obtained after chromatography (petroleum ether:ether; 1:1) 0.06 g (46%) of JWH-399 as a brown oil: ¹H NMR (300 MHz, CDCl₃) δ 1.02 (t, *J* = 7.2 Hz, 3H), 1.86 (sextet, *J* = 7.5 Hz, 2H), 2.54 (s, 3H), 4.13 (t, *J* = 7.2 Hz, 2H), 7.03 (t, *J* = 7.2 Hz, 1H), 7.16–7.23 (m, 2H), 7.35 (d, *J* = 8.4 Hz, 1H), 7.52 (t, *J* = 7.5 Hz, 2H), 7.63–7.68 (m, 2H), 8.17 (d, *J* = 8.4 Hz, 1H), 8.41 (d, *J* = 8.4 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 11.5, 12.7, 22.9, 44.9, 109.6, 114.7, 121.1, 122.1, 122.4, 124.7, 125.5, 126.1, 126.9, 127.5, 127.7, 131.1, 131.6, 133.7, 136.2, 139.8, 145.9, 192.4; GC/MS (EI) *m/z* (rel intensity) 361 (100), 346 (26), 326 (56), 304 (29); HRMS (ES⁺) *m/z* calcd for C₂₃H₂₀ClNO: 361.1233; found: 361.1232.

5.1.11. 1-Pentyl-3-(4-chloro-1-naphthoyl)indole, (JWH-398, 10, R = C₅H₁₁, R' = H, X = Cl)—JWH-398 was prepared by procedure A employed for the synthesis of JWH-400. From 0.10 g (0.33 mmol) of 3-(4-chloro-1-naphthoyl)indole, 0.08 g (1.5 mmol)

of crushed KOH and 0.10 g (0.65 mmol) of 1-bromopentane there was obtained after chromatography (petroleum ether:ether, 9:1) 0.06 g (48%) of JWH-398 as a brown oil; ^1H NMR (500 MHz, CDCl_3) δ 0.87 (t, J = 6.8 Hz, 3H), 1.28-1.34 (m, 4H), 1.82-1.86 (m, 2H), 4.09 (t, J = 7.0 Hz, 2H), 7.37 (s, 1H), 7.39-7.42 (m, 3H), 7.56 (t, J = 7.5 Hz, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.65-7.68 (m, 2H), 8.25 (d, J = 8.5 Hz, 1H), 8.40 (d, J = 8.5 Hz, 1H), 8.51-8.53 (m, 1H); ^{13}C NMR (75.5 MHz, CDCl_3) δ 13.9, 22.2, 28.9, 29.5, 47.3, 110.1, 117.4, 122.9, 123.0, 123.8, 124.6, 125.0, 125.6, 126.5, 126.9, 127.5, 127.5, 131.0, 132.0, 133.8, 137.1, 138.0, 138.4, 191.0; GC/MS (EI) m/z (rel intensity) 375 (100), 358 (51), 318 (75), 214 (86); HRMS (ES^+) m/z calcd for $\text{C}_{24}\text{H}_{22}\text{ClNO}$: 375.1390; found: 375.1383

5.1.12. 2-Methyl-1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-397, 10, R = C_5H_{11} , R' = CH_3 , X = Cl)—JWH-397 was prepared by procedure A employed for the synthesis of JWH-400. From 0.15 g (0.47 mmol) of 2-methyl-3-(4-chloro-1-naphthoyl)indole, 0.12 g (2.1 mmol) of crushed KOH and 0.14 g (0.94 mmol) of 1-bromopentane there was obtained after chromatography (petroleum ether:ether, 8:2) 0.05 g (31%) of JWH-397 as a yellow oil: ^1H NMR (300 MHz, CDCl_3) δ 0.97 (t, J = 6.9 Hz, 3H), 1.37-1.42 (m, 4H), 1.80-1.85 (m, 2H), 2.55 (s, 3H), 4.15 (t, J = 7.5 Hz, 2H), 7.01-7.06 (m, 1H), 7.16-7.24 (m, 2H), 7.35 (d, J = 8.1 Hz, 1H), 7.53 (t, J = 7.2 Hz, 2H), 7.63-7.68 (m, 2H), 8.17 (d, J = 8.4 Hz, 1H), 8.41 (d, J = 8.7 Hz, 1H); ^{13}C NMR (75.5 MHz, CDCl_3) δ 12.7, 14.0, 22.4, 29.1, 29.3, 43.4, 109.6, 114.7, 121.1, 122.1, 122.4, 124.7, 125.5, 126.2, 127.0, 127.4, 127.7, 131.1, 131.6, 133.7, 136.1, 139.9, 145.9, 192.4; GC/MS (EI) m/z (rel intensity) 389 (100), 374 (81), 354 (43), 332 (30), 304 (27); HRMS (ES^+) m/z calc'd for $\text{C}_{25}\text{H}_{24}\text{ClNO}$: 389.1546; found: 389.1541.

5.1.13. 1-Acetyl-4-bromonaphthalene (24, X = Br)—To a stirred solution of 1.00 g (4.8 mmol) of 1-bromonaphthalene in 15 mL of carbon disulfide at 0 °C in a flame-dried flask under N_2 was added 0.42 g (5.3 mmol) of acetyl chloride. This solution was stirred at 0 °C for 10 min and 0.84 g (6.3 mmol) of AlCl_3 was added. The reaction was stirred at 0 °C for 3 days followed by 2 days of stirring at ambient temperature. The reaction mixture was poured over ice and concentrated HCl, extracted with ether, washed with NaHCO_3 and brine. After drying (MgSO_4) the solution was concentrated *in vacuo* and purified by chromatography (petroleum ether: ether, 95:5) to give 0.75 g (62%) of 1-acetyl-4-bromonaphthalene as a brown oil: ^1H NMR (300 MHz, CDCl_3) δ 2.74 (s, 3H), 7.65-7.69 (m, 2H), 7.74 (d, J = 6 Hz, 1H), 7.83 (d, J = 6 Hz, 1H), 8.32-8.35 (m, 1H), 8.72-8.75 (m, 1H); ^{13}C NMR (75.5 MHz, CDCl_3) δ 30.1, 126.4, 127.5, 127.8, 128.2, 128.4, 128.7, 128.7, 131.2, 132.3, 135.2, 201.0; GC/MS (EI) m/z (rel intensity) 248 (46), 233 (100), 205 (44). The data agree in all respects with those reported previously.⁴³

5.1.14. 4-Bromo-1-naphthoic Acid (22, X = Br)—Acid 22 (X = Br) was prepared by the procedure employed for the conversion of 1-acetyl-4-chloronaphthalene to 4-chloro-1-naphthoic acid. From 0.52 g (2.09 mmol) of 1-acetyl-4-bromonaphthalene there was obtained after chromatography (petroleum ether: ether, 95:5) 0.55 g (57%) of methyl 4-bromo-1-naphthoate as a yellow oil: ^1H NMR (500 MHz, CDCl_3) δ 4.00 (s, 3H), 7.63 (p, J = 8.4 Hz, 2H), 7.77 (d, J = 7.5 Hz, 1H), 7.95 (d, J = 7.5 Hz, 1H), 8.30 (d, J = 8.0 Hz, 1H), 8.96 (d, J = 8.0 Hz, 1H); ^{13}C NMR (75.5 MHz, CDCl_3) δ 52.3, 126.3, 126.9, 127.6, 127.7, 128.5, 128.8, 128.9, 130.1, 132.1, 132.4, 167.4; GC/MS (EI) m/z (rel intensity) 264 (65), 233 (98), 295 (35), 126 (100).

Saponification of 0.50 g (1.9 mmol) of methyl 4-bromo-1-naphthoate gave 0.35 g (73%) of 4-bromo-1-naphthoic acid as a white solid: m.p. 215-217 °C (lit m.p. 217-219 °C⁴⁴); ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.74-7.77 (m, 2H), 8.00 (q, J = 9, 12 Hz, 2H), 8.25-8.28 (m, 1H), 8.90-8.93 (m, 1H), 13.3 (br s, 1H); ^{13}C NMR (75.5 MHz, $\text{DMSO}-d_6$) δ 63.4, 126.7, 127.5, 127.5, 128.6, 129.0, 129.9, 130.5, 131.8, 132.3, 168.6.

5.1.15. 3-(4-Bromo-1-naphthoyl)indole (18, R = H, Ar = 4-bromonaphthyl)—3-(4-Bromo-1-naphthoyl)indole was prepared by the procedure employed for the synthesis of 3-(4-chloro-1-naphthoyl)indole. From 0.14 g (1.2 mmol) of indole and 4-bromo-1-naphthoyl chloride prepared from 0.27 g (1.07 mmol) of 4-bromo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ether, 2:1) 0.29 g (76%) of 3-(4-bromo-1-naphthoyl)indole as a brown solid: ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.27-7.33 (m, 2H), 7.53-7.57 (m, 1H), 7.59-7.64 (m, 2H), 7.71 (d, J = 8.4 Hz, 1H), 7.75-7.80 (m, 1H), 7.98 (d, J = 7.5 Hz, 1H), 8.07 (d, J = 8.1 Hz, 1H), 8.25 (d, J = 8.4 Hz, 1H), 8.37-8.34 (m, 1H), 12.18 (br, 1H); ^{13}C NMR (75.5 MHz, $\text{DMSO}-d_6$) δ 113.0, 117.6, 121.9, 122.8, 123.9, 124.0, 126.2, 126.6 (br), 127.3, 128.2, 128.6, 129.7, 131.8, 131.9, 137.5, 137.7, 139.4.

5.1.16. 1-Propyl-3-(4-bromo-1-naphthoyl)indole (JWH-386, 11, R = C_3H_7 , R' = H, X = Br)—A. JWH-386 was prepared by procedure A employed for the synthesis of JWH-400. From 0.30 g (0.86 mmol) of 3-(4-bromo-1-naphthoyl)indole, 0.22 g (3.8 mmol) of crushed KOH and 0.31 g (1.8 mmol) of 1-iodopropane there was obtained after chromatography (petroleum ether: ether, 9:1) 0.040 g (12%) of JWH-386 a white solid: m.p. 186-188 °C; ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 0.77 (t, J = 7.2 Hz, 3H), 1.72 (sextet, J = 7.2 Hz, 2H), 4.15 (t, J = 6.9 Hz, 2H), 7.32-7.36 (m, 2H), 7.58-7.66 (m, 3H), 7.74 (m, 1H), 7.83 (s, 1H), 8.03 (t, J = 9 Hz, 2H), 8.27 (d, J = 8.4 Hz, 1H), 8.32-8.35 (m, 1H); ^{13}C NMR (75.5 MHz, $\text{DMSO}-d_6$) δ 11.4, 23.2, 48.1, 111.6, 116.4, 122.2, 123.1, 123.9, 124.0, 126.6, 126.7, 127.2, 128.2, 128.6, 129.8, 131.8, 131.8, 137.4, 139.3, 140.4, 162.3, 190.4; GC/MS (EI) m/z (rel intensity) 391 (64), 376 (22), 364 (23), 207 (100), 186 (67); HRMS (EI⁺) m/z calcd for $\text{C}_{22}\text{H}_{18}\text{BrNO}$: 391.0572; found: 391.0590.

B. JWH-386 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.07 g (0.44 mmol) of 1-propylindole and 0.10 g (0.40 mmol) of 4-bromo-1-naphthoic acid there was obtained after column chromatography (petroleum ether: ethyl acetate, 9:1) 0.12 g (72%) of 1-propyl-3-(4-bromo-1-naphthoyl)indole as a yellow solid: m.p. 186-187 °C. The spectroscopic properties were identical to those of material prepared by method A.

5.1.17. 2-Methyl-3-(4-bromo-1-naphthoyl)indole (18, R = CH_3 , Ar = 4-bromonaphthyl)—2-Methyl-3-(4-bromo-1-naphthoyl)indole was prepared by the procedure employed for the synthesis of 3-(4-chloro-1-naphthoyl)indole. From 0.12 g (0.88 mmol) of 2-methylindole and freshly prepared 4-bromo-1-naphthoyl chloride from 0.20 g (0.80 mmol) of 4-bromo-1-naphthoic acid, there was obtained 0.13 g (44%) of 2-methyl-3-(4-bromo-1-naphthoyl)indole as a yellow oil: ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 2.76 (s, 3H), 6.99 (d, J = 8.0 Hz, 2H), 7.38-7.50 (m, 2H), 7.80 (d, J = 8.0 Hz, 2H), 7.84-7.86 (m, 2H), 8.03 (d, J = 8.0 Hz, 1H), 8.36-8.38 (m, 1H), 12.09 (br, 1H); ^{13}C NMR (75.5 MHz, $\text{DMSO}-d_6$) δ 15.8, 111.7, 114.0, 120.5, 122.6, 122.8, 125.0, 125.1, 126.0, 126.5, 128.1, 128.5, 129.0, 131.5, 131.7, 132.1, 135.9, 142.4, 148.7, 188.4.

5.1.18. 2-Methyl-1-propyl-3-(4-bromo-1-naphthoyl)indole (JWH-395, 11, R = C_3H_7 , R' = CH_3 , X = Br)—A. JWH-395 was prepared by procedure A employed for the synthesis of JWH-400. From 0.22 g (0.60 mmol) of 2-methyl-1-propyl-3-(4-bromo-1-naphthoyl)indole, 0.15 g (2.72 mmol) of crushed KOH and 0.21 g (1.21 mmol) of 1-iodopropane there was obtained after chromatography (petroleum ether: ether, 7:3) 0.12 g (50%) of 2-methyl-1-propyl-3-(4-bromo-1-naphthoyl)indole as a green solid, m.p. 51-53 °C; ^1H NMR (300 MHz, CDCl_3) δ 1.02 (t, J = 7.5 Hz, 3H), 1.85 (sextet, J = 7.5 Hz, 2H), 2.54 (s, 3H), 4.11 (t, J = 7.5 Hz, 2H), 7.04 (t, J = 7.2 Hz, 1H), 7.14-7.24 (m, 2H), 7.35 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 7.5 Hz, 1H), 7.51 (t, J = 7.2 Hz, 1H), 7.64 (t, J = 7.2 Hz, 1H), 7.86 (d, J = 7.5 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H); ^{13}C NMR (75.5 MHz,

CDCl_3) δ 11.5, 12.7, 22.9, 44.9, 109.7, 114.7, 121.1, 122.1, 122.4, 124.8, 125.8, 126.2, 126.9, 127.5, 127.7, 127.8, 129.3, 131.6, 132.3, 136.2, 140.7, 146.0, 192.3; GC/MS (EI) m/z (rel intensity) 405 (82), 390 (31), 326 (100), 309(24); HRMS (ES^+) m/z calcd for $\text{C}_{23}\text{H}_{20}\text{BrNO}$: 405.0728; found: 405.0721.

B. JWH-395 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.08 g (0.48 mmol) of 2-methyl-1-propylindole and 0.11 g (0.45 mmol) of 4-bromo-1-naphthoic acid there was obtained after column chromatography (petroleum ether: ethyl acetate, 8:2) 0.11 g (60%) of 2-methyl-1-propyl-3-(4-bromo-1-naphthoyl)indole as a green oil. The spectroscopic properties were identical to those of material prepared by method A.

5.1.19. 1-Pentyl-3-(4-bromo-1-naphthoyl)indole (JWH-387, 11, R = C_5H_{11} , R' = H, X = Br)—A. JWH-387 was prepared by procedure A employed for the synthesis of JWH-400. From 0.10 g (0.28 mmol) of 3-(4-bromo-1-naphthoyl)indole, 0.07 g (1.3 mmol) of crushed KOH and 0.09 g (0.57 mmol) of 1-bromopentane there was obtained after chromatography (petroleum ether: ether, 8:2) 0.022 g (18%) of JWH-387 as an orange oil: ^1H NMR (300 MHz, CDCl_3) δ 0.87 (t, J = 6.6 Hz, 3H), 1.25-1.31 (m, 4H), 1.80-1.85 (m, 2H), 4.09 (t, J = 7.2 Hz, 2H), 7.28 (s, 1H), 7.35-7.41 (m, 4H), 7.50-7.56 (m, 1H), 7.63-7.68 (m, 1H), 7.87 (d, J = 7.5 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 8.36 (d, J = 8.4 Hz, 1H), 8.48-8.51 (m, 1H); ^{13}C NMR (75.5 MHz, CDCl_3) δ 13.9, 22.2, 28.9, 29.48, 47.2, 110.1, 117.4, 122.9, 123.0, 123.8, 124.8, 125.8, 126.5, 126.9, 127.4, 127.5, 127.8, 128.8, 132.0, 132.2, 137.1, 137.9, 139.1, 191.0; GC/MS (EI) m/z (rel intensity) 419 (64), 402 (31), 362 (42), 334 (61), 214 (100); HRMS (EI^+) m/z calcd for $\text{C}_{24}\text{H}_{22}\text{BrNO}$: 419.0885; found: 419.0086.

B. JWH-387 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.08 g (0.44 mmol) of 1-pentylindole and 4-bromo-1-naphthoyl chloride prepared from 0.10 g (0.40 mmol) of 4-bromo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ethyl acetate, 9:1) 0.09 g (53%) of 1-pentyl-3-(4-bromo-1-naphthoyl)indole as an orange oil. The spectroscopic properties of material prepared by method B were identical to those prepared by method A.

5.1.20. 2-Methyl-1-pentyl-3-(4-bromo-1-naphthoyl)indole (JWH-394, 11, R = C_5H_{11} , R' = CH_3 , X = Br)—A. JWH-394 was prepared by procedure A employed for the synthesis of JWH-400. From 0.12 g (0.33 mmol) of 2-methyl-3-(4-bromo-1-naphthoyl)indole, 0.08 g (1.48 mmol) of crushed KOH and 0.10 g (0.66 mmol) of 1-bromopentane there was obtained after chromatography (petroleum ether: ether, 8:2) 0.014 g (10%) of 2-methyl-1-pentyl-3-(4-bromo-1-naphthoyl)indole as a green oil: ^1H NMR (500 MHz, CDCl_3) δ 0.96 (t, J = 7.0 Hz, 3H), 1.39-1.42 (m, 4H), 1.83 (p, J = 7.3 Hz, 2H), 2.55 (s, 3H), 4.15 (t, J = 7.8 Hz, 2H), 7.05 (t, J = 7.3 Hz, 1H), 7.19-7.24 (m, 2H), 7.35 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 7.5 Hz, 1H), 7.52 (t, J = 8.3 Hz, 1H), 7.65 (t, J = 8.0 Hz, 1H), 7.86 (d, J = 7.5 Hz, 1H), 8.16 (d, J = 8.0 Hz, 1H), 8.39 (d, J = 8.5 Hz, 1H); ^{13}C NMR (125.77 MHz, CDCl_3) δ 12.7, 14.0, 22.4, 29.1, 29.4, 43.4, 109.6, 114.7, 121.1, 122.1, 122.4, 124.8, 125.8, 126.2, 127.0, 127.5, 127.7, 127.8, 129.3, 131.6, 132.3, 136.1, 140.7, 145.9, 192.3; GC/MS (EI) m/z (rel intensity) 433 (100), 418 (93), 377 (31), 354 (98), 348 (27), 298 (40), 254 (42), 233 (80); HRMS (EI^+) m/z calcd for $\text{C}_{25}\text{H}_{24}\text{BrNO}$: 433.1041; found: 433.1041.

B. JWH-394 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.11 g (0.57 mmol) of 2-methyl-1-pentylindole and 0.13 g (0.52 mmol) of 4-bromo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ethyl acetate, 7:3) 0.16 g (73%) of 2-methyl-1-pentyl-3-

(4-bromo-1-naphthoyl)indole as a green oil. The spectroscopic properties were identical to those of material prepared by method A.

5.1.21. 1-Acetyl-4-iodonaphthalene (24, X = I)

To a stirred solution of 2.00 g (15.4 mmol) of AlCl_3 in 10 mL of freshly distilled CH_2Cl_2 under Ar at 0 °C was added dropwise 1.0 g (13.0 mmol) of acetyl chloride. The mixture was stirred at 0 °C for 10 min and 3.0 g (11.2 mmol) of 1-iodonaphthalene was added dropwise over 10 min. The reaction was stirred at 0 °C for 72 h then stirred at ambient temperature for 48 h. The reaction mixture was poured over ice and concentrated HCl, extracted into ether and dried (MgSO_4). The solvent was removed *in vacuo* and the crude product was chromatographed (petroleum ether: ether, 7:3) to give 1.9 g (55%) of 1-acetyl-4-iodonaphthalene as a brown oil, which was converted to the corresponding carboxylic acid without further purification: ^1H NMR (300 MHz, CDCl_3) δ 2.71 (s, 3H), 7.49 (d, J = 7.8 Hz, 1H), 7.58-7.64 (m, 2H), 8.08 (d, J = 7.5 Hz, 1H), 8.13-8.17 (m, 1H), 8.63-8.66 (m, 1H); ^{13}C NMR (75.5 MHz, CDCl_3) δ 30.2, 106.1, 126.5, 128.2, 128.6, 128.8, 130.4, 132.8, 134.6, 136.2, 136.3, 201.3; GC/MS (EI) m/z (rel intensity) 296(70), 281 (100), 253 (27), 126 (89). This compound was previously reported by Rajasekaran and Gnanasekaran, however no spectroscopic data were presented.⁴⁵

5.1.22. 4-Iodo-1-naphthoic acid (22, X = I)

Acid **22** (X = I) was prepared by the procedure employed for the conversion of 1-acetyl-4-chloronaphthalene to 4-chloro-1-naphthoic acid. From 2.0 g (6.75 mmol) of 1-acetyl-4-iodonaphthalene there was obtained after chromatography (petroleum ether: ether, 7:3) 1.2 g (56%) of methyl 4-iodo-1-naphthoate as a brown oil: ^1H NMR (500 MHz, CDCl_3) δ 4.03 (s, 3H), 7.63-7.69 (m, 2H), 7.83 (d, J = 7.5 Hz, 1H), 8.17 (d, J = 7.5 Hz, 1H), 8.21 (d, J = 8.0 Hz, 2H); ^{13}C NMR (125.77 MHz, CDCl_3) δ 52.4, 125.8, 126.2, 126.4, 127.8, 128.1, 128.5, 130.3, 133.0, 133.4, 136.5, 167.6; GC/MS (EI) m/z (rel intensity) 312 (100), 281 (84), 253 (22), 126 (76).

Saponification of 1.1 g (3.5 mmol) of methyl-4-iodo-1-naphthoate gave 0.90 g (86%) of 4-iodo-1-naphthoic acid as a white solid: m.p. 209 °C (lit. m.p. 213 °C⁴⁶); ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.72-7.74 (m, 2H), 7.84 (d, J = 8 Hz, 1H), 8.14 (dd, J = 3, 6.5 Hz, 1H), 8.27 (d, J = 7.5 Hz, 1H), 8.84 (dd, J = 3, 6.5 Hz, 1H), 13.35 (br s, 1H); ^{13}C NMR (125.77 MHz, $\text{DMSO}-d_6$) δ 106.1, 126.0, 126.8, 128.8, 128.9, 130.7, 131.5, 132.8, 134.4, 137.2, 168.8.

5.1.23. 1-Propyl-3-(4-iodo-1-naphthoyl)indole (JWH-423, **12**, R = C_3H_7 , R' = H, X = I)

JWH-423 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.11 g (0.70 mmol) of 1-propylindole and 0.21 g (0.70 mmol) of 4-iodo-1-naphthoic acid there was obtained after column chromatography (petroleum ether:ethyl acetate, 9:1) 0.022 g (7%) of 1-propyl-3-(4-iodo-1-naphthoyl)indole as a pale cream powder: m.p. 160-161 °C; ^1H NMR (500 MHz, CDCl_3) δ 0.79 (t, J = 7 Hz, 3H), 1.72-1.76 (m, 2H), 4.17 (t, J = 7 Hz, 2H), 7.33-7.35 (m, 2H), 7.43 (d, J = 7 Hz, 1H), 7.59 (t, J = 7.5 Hz, 1H), 7.64 (d, J = 7 Hz, 1H), 7.71 (t, J = 7.5 Hz, 1H), 7.81 (s, 1H), 7.98 (d, J = 8 Hz, 1H), 8.15 (d, J = 8.5 Hz, 1H), 8.28 (d, J = 7.5 Hz, 1H), 8.32 (d, J = 6.5 Hz, 1H); ^{13}C NMR (125.77 MHz, CDCl_3) δ 11.3, 23.1, 48.9, 101.9, 110.1, 117.5, 122.9, 123.0, 123.8, 126.3, 126.7, 126.9, 127.6, 128.2, 131.4, 132.5, 134.5, 136.4, 137.1, 138.0, 140.1, 191.0; GC/MS (EI) m/z (rel intensity) 439 (100), 422 (37), 410 (40), 186 (83); HRMS (ES^+) m/z calcd for $\text{C}_{22}\text{H}_{18}\text{INO}$: 440.0511; found: 440.0526.

5.1.24. 2-Methyl-1-propyl-3-(4-iodo-1-naphthoyl)indole (JWH-422, 12, R = C₃H₇, R' = CH₃, X = I)

JWH-422 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.12 g (0.67 mmol) of 2-methyl-1-propylindole and 0.20 g (0.67 mmol) of 4-iodo-1-naphthoic acid there was obtained after column chromatography (petroleum ether: ether, 7:3) 0.039 g (13%) of 2-methyl-1-propyl-3-(4-iodo-1-naphthoyl)indole as a green oil: ¹H NMR (500 MHz, CDCl₃) δ 1.03 (t, *J* = 7.5 Hz, 3H), 1.86 (sextet, *J* = 7.5 Hz, 2H), 2.55 (s, 3H), 4.14 (t, *J* = 7.5 Hz, 2H), 7.04 (t, *J* = 8 Hz, 1H), 7.18 (d, *J* = 8 Hz, 1H), 7.21 (t, *J* = 7.5 Hz, 1H), 7.28 (d, *J* = 7.5 Hz, 1H), 7.35 (d, *J* = 8.5 Hz, 1H), 7.49 (t, *J* = 7.8 Hz, 1H), 7.62 (t, *J* = 7.8 Hz, 1H), 8.07 (d, *J* = 8.5 Hz, 1H), 8.17 (d, *J* = 7 Hz, 1H), 8.23 (d, *J* = 8.5 Hz, 1H); ¹³C NMR (125.77 MHz, CDCl₃) δ 11.5, 12.7, 22.9, 44.9, 101.7, 109.6, 114.7, 121.1, 122.1, 122.4, 126.1, 126.3, 126.9, 127.7, 128.1, 131.0, 132.5, 134.6, 136.2, 136.9, 141.6, 145.9, 192.3; GC/MS (EI) *m/z* (rel intensity) 453 (100), 326 (58); HRMS (ES⁺) *m/z* calcd for C₂₃H₂₀INO: 454.0668; found: 454.0665.

5.1.25. 1-Pentyl-3-(4-iodo-1-naphthoyl)indole (JWH-421, 12, R = C₅H₁₁, R' = H, X = I)

JWH-421 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.13 g (0.67 mmol) of 1-pentylindole and 0.20 g (0.67 mmol) of 4-iodo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ether, 1:1) 0.047 g (15%) of 1-pentyl-3-(4-iodo-1-naphthoyl)indole as a peach colored oil: ¹H NMR (500 MHz, CDCl₃) δ 0.89 (t, *J* = 7.5 Hz, 3H), 1.30-1.36 (m, 4H), 1.83-1.86 (m, 2H), 4.08 (t, *J* = 7.5 Hz, 2H), 7.35 (s, 1H), 7.36-7.42 (m, 4H), 7.51 (t, *J* = 8 Hz, 1H), 7.62 (t, *J* = 8 Hz, 1H), 8.15 (d, *J* = 8.5 Hz, 1H), 8.19 (d, *J* = 7 Hz, 1H), 8.22 (d, *J* = 8.5 Hz, 1H), 8.48-8.50 (m, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 13.9, 22.2, 28.9, 29.5, 47.3, 101.9, 110.1, 117.5, 122.9, 123.0, 123.8, 126.3, 126.7, 126.9, 127.6, 128.2, 131.4, 132.5, 134.5, 136.4, 137.1, 138.0, 140.1, 191.0; GC/MS (EI) *m/z* (rel intensity) 467 (33), 410 (21), 214 (100), 144 (53); HRMS (ES⁺) *m/z* calcd for C₂₄H₂₂INO: 468.0824; found: 468.0811.

5.1.26. 2-Methyl-1-pentyl-3-(4-iodo-1-naphthoyl)indole (JWH-420, 12, R = C₅H₁₁, R' = CH₃, X = I)

JWH-420 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.10 g (0.50 mmol) of 2-methyl-1-pentylindole and 0.15 g (0.50 mmol) of 4-iodo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ether, 7:3) 0.065 g (27%) of 2-methyl-1-pentyl-3-(4-iodo-1-naphthoyl)indole as a brown oil: ¹H NMR (500 MHz, CDCl₃) δ 0.95 (t, *J* = 6.8 Hz, 3H), 1.39-1.42 (m, 4H), 1.81-1.84 (m, 2H), 2.55 (s, 3H), 4.15 (t, *J* = 7.5 Hz, 2H), 7.05 (t, *J* = 7.5 Hz, 1H), 7.19 (d, *J* = 8 Hz, 1H), 7.22 (t, *J* = 7.5 Hz, 1H), 7.28-7.29 (m, 1H), 7.35 (d, *J* = 8 Hz, 1H), 7.50 (t, *J* = 7.5 Hz, 1H), 7.62 (t, *J* = 8 Hz, 1H), 8.08 (d, *J* = 8.5 Hz, 1H), 8.17 (d, *J* = 7.5 Hz, 1H), 8.23 (d, *J* = 8.5 Hz, 1H); ¹³C NMR (125.77 MHz, CDCl₃) δ 12.7, 13.9, 22.4, 29.1, 29.3, 43.4, 101.7, 109.6, 114.7, 121.1, 122.2, 122.4, 126.2, 126.3, 126.9, 127.7, 128.1, 131.0, 132.6, 134.6, 136.1, 136.9, 141.6, 145.9, 192.3; GC/MS (EI) *m/z* (rel intensity) 481 (100), 466 (62), 354 (48), 281 (41); HRMS (ES⁺) *m/z* calcd for C₂₅H₂₄INO: 482.0981; found: 482.0987.

5.1.27. 1-Propyl-3-(8-chloro-1-naphthoyl)indole (JWH-456, 14, R = C₃H₇, R' = H)

JWH-456 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414), however the indole was stirred with dimethylaluminum chloride for 1h and the acid chloride and indole mixture was stirred for 6 h at ambient temperature. From 0.700 g (3.34 mmol) of 1-propylindole and 0.549 g (2.66 mmol) of 8-chloro-1-naphthoic acid²⁸ there was obtained after chromatography (petroleum

ether: ether, 2:1) 0.425 g (46%) of 1-propyl-3-(8-chloro-1-naphthoyl)indole as a yellow gum: ^1H NMR (300 MHz, CDCl_3) δ 0.85 (t, J = 6 Hz, 3H), 1.75-1.87 (m, 2H), 4.00 (t, J = 6 Hz, 2H), 7.20 (s, 1H), 7.29-7.37 (m, 3H), 7.41 (t, J = 9 Hz, 1H), 7.53-7.57 (m, 3H), 7.85 (d, J = 9 Hz, 1H), 7.96 (dd, J = 6 Hz, 3 Hz, 1H), 8.35 (s, 1H); ^{13}C NMR (75.5 MHz, CDCl_3) δ 11.2, 23.0, 48.7, 109.9, 118.6, 122.5, 122.7, 123.3, 125.4, 126.2, 126.7, 127.5, 127.8, 128.1, 128.7, 129.9, 130.8, 135.6, 137.0, 137.1, 139.0, 192.5; GC/MS (EI) m/z (rel intensity) 347 (97), 312 (100), 270 (42); HRMS (ES^+) m/z calcd for $\text{C}_{12}\text{H}_{18}\text{ClNO}$: 348.1155; found: 348.1161.

5.1.28. 2-Methyl-1-propyl-3-(8-chloro-1-naphthoyl)indole (JWH-461, 14, R = C_3H_7 , R' = CH_3)

JWH-461 was prepared by the procedure employed for the synthesis of 1-propyl-3-(8-chloro-1-naphthoyl)indole (JWH-456). From 0.446 g (2.36 mmol) of 2-methyl-1-propylindole and 0.408 g (1.97 mmol) of 8-chloro-1-naphthoic acid there was obtained after chromatography (petroleum ether: ether, 3:1) 0.447 g (67%) of 2-methyl-1-propyl-3-(8-chloro-1-naphthoyl)indole as a pale red gum: ^1H NMR (300 MHz, CDCl_3) δ 0.95-0.99 (m, 3H), 1.78 (s, 3H), 2.97 (s, 1 1/2H), 4.04 (m, 2H), 6.14 (br s, 1/2H), 6.72 (br s, 1/2H), 7.05-7.08 (m, 1H), 7.28 (d, J = 6 Hz, 1H), 7.35-7.40 (m, 1H), 7.44-7.52 (m, 3H), 7.82 (d, J = 6 Hz, 1H), 7.92 (d, J = 6 Hz, 1H), 8.69 (br s, 1/2H). ^{13}C NMR (75.5 MHz, CDCl_3) δ 11.4, 12.5, 22.9, 44.7, 109.5, 114.4, 119.9, 121.5, 122.6, 126.0, 126.1, 126.8, 127.7, 127.8, 128.6, 129.7, 130.7, 134.2, 135.7, 136.0, 140.9, 145.9, 193.6. GC/MS (EI) m/z (rel intensity) 361 (23), 326 (100), 284 (68), 269 (23); HRMS (ES^+) m/z calcd for $\text{C}_{23}\text{H}_{20}\text{ClNO}$: 362.1312; found: 362.1310

5.1.29. 1-Pentyl-3-(8-chloro-1-naphthoyl)indole (JWH-457, 14, R = C_5H_{11} , R' = H)

JWH-457 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414), however the indole was stirred with dimethylaluminum chloride for 1h and the acid chloride and indole mixture was stirred for 6 h at ambient temperature. From 0.780 g (2.90 mmol) of 1-propylindole and 0.507 g (2.42 mmol) of 8-chloro-1-naphthoic acid there was obtained after chromatography (petroleum ether: ether, 3:1) 0.304 g (33%) of 1-pentyl-3-(8-chloro-1-naphthoyl)indole (JWH-457) as an dark brown oil: ^1H NMR (300 MHz, CDCl_3) δ 0.79 (t, J = 6 Hz, 3H), 1.08-1.26 (m, 4H), 1.66-1.75 (m, 2H), 3.94 (t, J = 6 Hz, 2H), 7.15 (s, 1H), 7.26-7.32 (m, 3H), 7.34 (m, 1H), 7.45-7.53 (m, 3H), 7.79 (d, J = 9 Hz, 1H), 7.90 (dd, J = 9 Hz, 3 Hz, 1H), 8.39 (s, 1H); ^{13}C NMR (75.5 MHz, CDCl_3) δ 13.7, 21.9, 28.6, 29.1, 46.8, 109.8, 118.4, 122.4, 122.5, 123.2, 125.3, 126.0, 126.6, 127.4, 127.7, 127.9, 128.6, 129.8, 130.6, 135.4, 136.8, 137.0, 138.8, 192.3; GC/MS (EI) m/z (rel intensity) 375 (80), 340 (100), 270 (48); HRMS (ES^+) m/z calcd for $\text{C}_{24}\text{H}_{22}\text{ClNO}$: 376.1468; found: 376.1459

5.1.30. 2-Methyl-1-pentyl-3-(8-chloro-1-naphthoyl)indole (JWH-462, 14, R = C_5H_{11} , R' = CH_3)

JWH-462 was prepared by the procedure employed for the synthesis of 1-propyl-3-(8-chloro-1-naphthoyl)indole (JWH-456). From 0.746 g (3.67 mmol) of 2-methyl-1-pentylindole and 0.632 g (3.06 mmol) of 8-chloro-1-naphthoic acid there was obtained after column chromatography (petroleum ether: ether, 3:1) 0.644 g (54%) of 2-methyl-1-pentyl-3-(8-chloro-1-naphthoyl)indole as a dark brown oil: ^1H NMR (300 MHz, CDCl_3) δ 0.85-0.88 (m, 3H), 1.31-1.41 (m, 4H), 1.74 (s, 3H), 2.96 (s, 1 1/2H), 3.96-4.07 (m, 2H), 6.15 (br s, 1/2H), 6.71 (br s, 1/2H), 7.03 (m, 1H), 7.26 (d, J = 6 Hz, 1H), 7.33 (t, J = 9 Hz, 1H), 7.44-7.50 (m, 3H), 7.78 (d, J = 6 Hz, 1H), 7.88 (d, J = 6 Hz, 1H), 8.71 (br s, 1/2H). ^{13}C NMR (75.5 MHz, CDCl_3) δ 12.2, 13.6, 21.9, 28.6, 28.9, 42.7, 109.3, 113.9, 119.5, 121.3, 122.2, 125.6, 125.8, 126.4, 127.3, 127.5, 128.2, 129.4, 130.2, 135.4, 135.7, 140.6, 144.1, 145.5, 193.1. GC/MS (EI) m/z (rel intensity) 389 (21), 354 (100), 284 (81), 269 (25); HRMS (ES^+) m/z calcd for $\text{C}_{25}\text{H}_{24}\text{ClNO}$: 390.1625; found: 390.1616.

5.1.31. 8-Bromo-1-naphthoic acid (27)

To a mixture of 3.9 mL (67 mmol) of acetic acid and 0.40 mL (22.2 mmol) of H₂O was added with stirring 1.0 g (2.70 mmol) of anhydro-8-hydroxymercuri-1-naphthoic acid²⁶ and the suspension was stirred at 0 °C for 10 min. A solution of 0.89 g (8.66 mmol) of NaBr in 3.2 mL of water and 0.43 g (2.70 mmol) of bromine were added sequentially and the reaction was slowly heated to 100 °C. After cooling to ambient temperature the mixture was poured into ice and 0.57 g (84%) of 8-bromo-1-naphthoic acid was filtered out as a cream colored solid: m.p. 173-174 °C (lit. m.p. 174-175 °C²⁶); ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.49 (t, *J* = 7.8 Hz, 1H), 7.61 (t, *J* = 7.3 Hz, 1H), 7.68 (d, *J* = 7.0 Hz, 1H), 7.96 (d, *J* = 7.3 Hz, 1H), 8.07 (d, *J* = 8.0 Hz, 1H), 8.11 (d, *J* = 8.0 Hz, 1H), 13.32 (s, 1H); ¹³C NMR (125.77 MHz, DMSO-*d*₆) δ 119.3, 126.3, 127.6, 128.0, 128.3, 129.4, 131.2, 133.6, 133.9, 135.7, 171.3.

5.1.32. 1-Propyl-3-(8-bromo-1-naphthoyl)indole (JWH-428, 15, R = C₃H₇, R' = H)

JWH-428 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.08 g (0.53 mmol) of *N*-propylindole and 0.12 g (0.48 mmol) of 8-bromo-1-naphthoic acid there was obtained after column chromatography (petroleum ether: ethyl acetate, 8:2) 0.09 g (48%) of 1-propyl-3-(8-bromo-1-naphthoyl)indole as an orange solid: m.p. 101-102 °C; ¹H NMR (Ambient Temperature, 500 MHz, DMSO-*d*₆) δ 0.74 (t, *J* = 7.0 Hz, 3H), 1.71 (q, *J* = 7.0 Hz, 2H), 4.14-4.18 (m, 2H), 7.27-7.33 (m, 2H), 7.49 (t, *J* = 8.0 Hz, 1H), 7.61 (t, *J* = 7.0 Hz, 2H), 7.67 (t, *J* = 7.5 Hz, 1H), 7.88 (d, *J* = 7.0 Hz, 1H), 8.12 (d, *J* = 8.0 Hz, 1H), 8.16 (d, *J* = 8.0 Hz, 1H); ¹³C NMR (125.77 MHz, DMSO-*d*₆) δ 11.3, 23.1, 48.0, 111.4, 118.3, 119.6, 122.1, 122.7, 123.5, 126.2, 126.8, 127.4, 128.4, 129.1, 129.5, 130.7, 133.5, 136.1, 137.3, 139.0, 140.0, 191.5; GC/MS (EI) *m/z* (rel intensity) 391 (10), 312 (100), 270 (99), 254 (26), 241 (25); HRMS (ES⁺) *m/z* calcd for C₂₂H₁₈BrNO: 392.0650; found: 392.0637.

At 100 °C: ¹H NMR (500 MHz, DMSO-*d*₆) δ 0.82 (t, *J* = 7.3 Hz, 3H), 1.78 (sextet, *J* = 7.3 Hz, 2H), 4.15 (t, *J* = 7.5 Hz, 2H), 7.24 (t, *J* = 7.5 Hz, 1H), 7.29 (t, *J* = 7.5 Hz, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.49 (s, 1H), 7.56 (d, *J* = 8.5 Hz, 1H), 7.60 (d, *J* = 7.0 Hz, 1H), 7.65 (t, *J* = 7.5 Hz, 1H), 7.86 (d, *J* = 7.5 Hz, 1H), 8.09 (d, *J* = 8.5 Hz, 1H), 8.13 (t, *J* = 7.8 Hz, 2H).

5.1.33. 2-Methyl-1-propyl-3-(8-bromo-1-naphthoyl)indole (JWH-429, 15, R = C₃H₇, R' = CH₃)

JWH-429 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.13 g (0.66 mmol) of 2-methyl-1-propylindole and 0.15 g (0.60 mmol) of 8-bromo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ethyl acetate, 8:2) 0.04 g (16%) of 2-methyl-1-propyl-3-(8-bromo-1-naphthoyl)indole as a green oil: ¹H NMR (Ambient Temperature, 500 MHz, DMSO-*d*₆) δ 0.81-0.90 (m, 3H), 1.65-1.76 (m, 2H), 2.89 (s, 1 1/2H), 4.23-4.24 (m, 2H), 6.63-6.66 (m, 1/2H), 7.01-7.03 (m, 1/2H), 7.26-7.27 (m, 1/2H), 7.43-7.54 (m, 2 1/2 H), 7.64 (t, *J* = 7.5 Hz, 1H), 7.83-7.91 (m, 1H), 8.11-8.17 (m, 2H), 8.39 (br s, 1/2H); (At 100 °C: ¹H NMR (500 MHz, DMSO-*d*₆) δ 0.89 (t, *J* = 7.5 Hz, 3H), 1.76 (sextet, *J* = 7.3 Hz, 2H), 2.89 (br s, 3H), 4.17 (t, *J* = 7.0 Hz, 2H), 6.92 (br s, 1H), 7.13 (t, *J* = 7.5 Hz, 1H), 7.45 (t, *J* = 7.5 Hz, 3H), 7.63 (t, *J* = 7.5 Hz, 1H), 7.83 (d, *J* = 7.5 Hz, 1H), 8.07 (d, *J* = 8.0 Hz, 1H), 8.12 (d, *J* = 8.5 Hz, 1H); ¹³C NMR (75.5 MHz, DMSO-*d*₆) δ 11.5, 14.3, 23.0, 44.7, 109.5, 120.0, 120.2, 121.4, 121.6, 122.7, 125.9, 126.6, 127.4, 127.7, 128.6, 129.2, 130.16, 132.9, 136.1, 142.2, 144.4, 146.0, 193.5. GC/MS (EI) *m/z* (rel intensity) 405 (10), 326 (100), 284 (79), 269 (31); HRMS (ES⁺) *m/z* calcd for C₂₃H₂₀BrNO: 406.0807; found: 406.0788.

5.1.34. 1-Pentyl-3-(8-bromo-1-naphthoyl)indole (JWH-424, 15, R = C₅H₁₁, R' = H)

JWH-424 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.12 g (0.66 mmol) of *N*-pentylindole and 0.15 g (0.60 mmol) of 8-bromo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ethyl acetate, 7:3) 0.20 g (78%) of *N*-pentyl-3-(8-bromo-1-naphthoyl)indole as a brown oil: ¹H NMR (Ambient Temperature, 500 MHz, DMSO-*d*₆) δ 0.86 (t, *J* = 7.0 Hz, 3H), 1.22-1.32 (m, 4H), 1.77-1.81 (m, 2H), 4.00-4.02 (m, 2H), 7.19-7.29 (m, 1H), 7.31-7.43 (m, 4H), 7.53 (t, *J* = 7.5 Hz, 1H), 7.62 (d, *J* = 7.0 Hz, 1H), 7.80 (d, *J* = 8.5 Hz, 1H), 7.96 (d, *J* = 8.0 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 14.0, 22.2, 28.8, 29.4, 47.1, 110.1, 119.3, 120.2, 122.7, 122.8, 123.5, 125.4, 126.7, 126.9, 128.1, 128.7, 129.5, 130.4, 133.1, 136.0, 137.1, 137.3, 140.1, 192.3; GC/MS (EI) *m/z* (rel intensity) 421 (3), 340 (100), 270 (58); HRMS (ES⁺) *m/z* calcd for C₂₄H₂₂BrNO: 420.0963; found: 420.0959.

5.1.35. 2-Methyl-1-pentyl-3-(8-bromo-1-naphthoyl)indole (JWH-425, 15, R = C₅H₁₁, R' = CH₃)

JWH-425 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.13 g (0.66 mmol) of 2-methyl-1-pentylindole and 0.15 g (0.60 mmol) of 8-bromo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ethyl acetate, 9:1) 0.04 g (15%) of 2-methyl-1-pentyl-3-(8-bromo-1-naphthoyl)indole as a brown oil: ¹H NMR (Ambient Temperature, 500 MHz, DMSO-*d*₆) δ 0.83-0.88 (m, 3H), 1.25-1.34 (m, 4H), 1.64-1.77 (m, 2H), 2.91 (s, 1 1/2H), 4.21-4.27 (m, 2H), 5.89 (br s, 1/2H), 6.67 (br s, 1/2H), 7.04 (br s, 1/2H), 7.27 (br s, 1H), 7.48-7.52 (m, 2 1/2H), 7.65 (t, *J* = 7.5 Hz, 1H), 7.86-7.91 (m, 1H), 8.13-8.17 (m, 1 1/2H), 8.41 (br s, 1/2H); ¹³C NMR (125.77 MHz, DMSO-*d*₆) δ 12.7, 14.0, 22.4, 29.1, 29.4, 43.4, 109.7, 120.1, 121.4, 121.7, 122.7, 125.9, 126.6, 127.4, 127.5, 128.6, 130.1, 132.9, 133.4, 135.4, 136.1, 142.2, 144.3, 146.0, 193.5. GC/MS (EI) *m/z* (rel intensity) 433 (6), 354 (78), 284 (100), 269 (28); HRMS (ES⁺) *m/z* calcd for C₂₅H₂₄BrNO: 434.1120; found: 434.1128.

5.1.36. 8-Iodo-1-naphthoic acid (28)

To 5.00 g (13.5 mmol) of anhydro-8-(hydroxymercuri)-1-naphthoic acid was added 9.63 g (58.0 mmol) of potassium iodide in 47 mL of H₂O. After dissolution, 3.42 g (13.5 mmol) of iodine was added and the reaction mixture was heated at reflux for 15 h. The solution was cooled to ambient temperature and a brown precipitate was filtered out. To the filtrate was added 1.62 g (10 mmol) of sodium thiosulfate in 9 mL of H₂O to destroy excess iodine and the solution was acidified by the dropwise addition of conc. HCl. The crude acid was filtered out, dissolved in hot acetone and concentrated *in vacuo*. Recrystallization from CHCl₃ gave 2.1 g (52%) of 8-iodo-1-naphthoic acid as a white solid: m.p. 155-156 °C (lit m.p. 164-165 °C²⁶); ¹H NMR (500 MHz, CDCl₃) δ 7.23 (t, *J* = 7.8 Hz, 1H), 7.51 (t, *J* = 7.5 Hz, 1H), 7.90 (d, *J* = 8.0 Hz, 1H), 7.93 (d, *J* = 7.5 Hz, 2H), 8.27 (d, *J* = 7.5 Hz, 1H), 12.63 (br s, 1H); ¹³C NMR (125.77 MHz, CDCl₃) δ 93.1, 125.1, 127.5, 129.5, 129.6, 131.4, 132.6, 133.5, 135.4, 141.9, 175.5.

5.1.37. 1-Propyl-3-(8-iodo-1-naphthoyl)indole (JWH-419, 16, R = C₃H₇, R' = H)

JWH-419 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.11 g (0.69 mmol) of 1-propylindole and 0.31 g (1.0 mmol) of 8-iodo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ether, 1:1) 0.064 g (21%) of *N*-propyl-3-(8-iodo-1-naphthoyl)indole as a brown oil: ¹H NMR (Ambient Temperature, 500 MHz, DMSO-*d*₆) δ 0.78 (t, *J* = 7.5 Hz, 3H), 1.73 (q, *J* = 7.0 Hz, 2H), 4.15-4.22 (m, 2H), 7.28-7.33 (m, 3H), 7.62-7.65 (m, 3 1/2H), 8.11-8.14 (m, 2H), 8.23 (d, *J* = 7.0 Hz, 1H); ¹³C NMR (125.77 MHz, DMSO-*d*₆) δ 11.3, 23.1, 48.0, 94.1, 111.3, 119.3, 122.3, 122.3, 122.7, 123.5, 125.9, 126.9, 127.8, 128.7, 130.0,

131.2, 131.9, 135.8, 137.3, 141.8, 141.9, 190.9; GC/MS (EI) m/z (rel intensity) 439 (2), 312 (100), 270 (63); HRMS (ES⁺) m/z calcd for C₂₂H₁₈INO: 440.0511; found: 440.0491.

5.1.38. 2-Methyl-1-propyl-3-(8-iodo-1-naphthoyl)indole (JWH-418, 16, R = C₃H₇, R' = CH₃)

JWH-418 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.14 g (0.84 mmol) of 2-methyl-1-propylindole and 0.36 g (1.2 mmol) of 8-iodo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ether, 3:7) 0.13 g (35%) of 2-methyl-1-propyl-3-(8-iodo-1-naphthoyl)indole as a brown oil: ¹H NMR (Ambient Temperature, 500 MHz, DMSO-*d*₆) δ 0.87-0.95 (m, 3H), 1.70-1.86 (m, 2H), 2.91 (s, 1 1/2H), 4.16-4.27 (m, 2H), 5.99-6.00 (m, 1/2H), 6.69-6.72 (m, 1/2H), 7.03-7.06 (m, 1/2H), 7.28-7.31 (m, 1 1/2H), 7.44-7.46 (m, 1H), 7.54-7.62 (m, 2H), 8.12-8.15 (m, 2H), 8.20-8.28 (m, 1H), 8.42 (br s, 1/2H); ¹³C NMR (125.77 MHz, DMSO-*d*₆) δ 11.5, 13.0, 23.0, 44.9, 92.9, 109.3, 109.7, 116.0, 120.5, 121.4, 121.7, 122.7, 125.7, 127.1, 128.0, 129.5, 130.7, 132.0, 135.9, 141.4, 143.8, 146.2, 192.8; GC/MS (EI) m/z (rel intensity) 453 (6), 326 (100), 284 (95), 269 (54), 254 (31); HRMS (ES⁺) m/z calcd for C₂₃H₂₀INO: 454.0668; found: 454.0662

5.1.39. 1-Pentyl-3-(8-iodo-1-naphthoyl)indole (JWH-416, 16, R = C₅H₁₁, R' = H)

JWH-416 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.10 g (0.57 mmol) of 1-pentylindole and 0.23 g (0.77 mmol) of 8-iodo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ether, 1:1) 0.040 g (11%) of 1-pentyl-3-(8-iodo-1-naphthoyl)indole as a yellow oil: ¹H NMR (Ambient Temperature, 500 MHz, DMSO-*d*₆) δ 0.88 (t, *J* = 7.0 Hz, 3H), 1.26-1.32 (m, 4H), 1.81-1.83 (m, 2H), 4.04-4.14 (m, 2H), 7.20 (t, *J* = 7.0 Hz, 1H), 7.38-7.43 (m, 2 1/2H), 7.54 (t, *J* = 7.0 Hz, 1H), 7.67 (d, *J* = 7.0 Hz, 1H), 7.95 (d, *J* = 8.0 Hz, 2H), 8.22 (d, *J* = 7.5 Hz, 1H); ¹³C NMR (125.77 MHz, CDCl₃) δ 13.9, 22.2, 28.8, 29.4, 47.1, 93.2, 109.9, 122.7, 123.0, 123.5, 125.1, 126.9, 127.0, 127.3, 128.5, 129.1, 129.5, 130.9, 132.0, 132.2, 135.7, 137.1, 141.6, 191.6; GC/MS (EI) m/z (rel intensity) 341 (100), 324 (48), 284 (86), 214 (85), 144 (48); HRMS (EI⁺) calcd for C₂₄H₂₂INO: 467.0747; found: 467.0742.

5.1.40. 2-Methyl-1-pentyl-3-(8-iodo-1-naphthoyl)indole (JWH-417, 16, R = C₅H₁₁, R' = CH₃)

JWH-417 was prepared by the procedure employed for the synthesis of 1-propyl-3-(4-fluoro-1-naphthoyl)indole (JWH-414). From 0.17 g (0.84 mmol) of 2-methyl-1-pentylindole and 0.25 g (0.84 mmol) of 8-iodo-1-naphthoic acid there was obtained after chromatography (petroleum ether: ether, 1:1) 0.25 g (64%) of 2-methyl-1-pentyl-3-(8-iodo-1-naphthoyl)indole as a brown oil: ¹H NMR (Ambient Temperature, 500 MHz, DMSO-*d*₆) δ 0.84-0.89 (m, 3H), 1.24-1.36 (m, 4H), 1.65-1.84 (m, 2H), 2.91 (s, 1 1/2H), 4.17-4.28 (m, 2H), 5.99-6.01 (m, 1/2H), 6.69-6.71 (m, 1/2H), 7.03-7.06 (m, 1/2H), 7.28-7.31 (m, 2H), 7.45-7.48 (m, 1H), 7.52-7.61 (m, 2H), 8.13-8.26 (m, 3H), 8.43 (br s, 1/2H); ¹³C NMR (125.77 MHz, DMSO-*d*₆) δ 13.0, 14.3, 22.3, 28.8, 29.4, 43.1, 93.8, 110.7, 119.7, 121.5, 122.0, 122.6, 123.0, 126.4, 127.9, 130.0, 131.1, 131.6, 135.8, 136.2, 141.7, 144.0, 146.3, 191.8; GC/MS (EI) m/z (rel intensity) 481 (3), 354 (70), 284 (100), 269 (45), 254 (28); HRMS (ES⁺) m/z calcd for C₂₅H₂₄INO: 482.0981; found: 482.0961.

5.2. Receptor binding experiments

5.2.1 Materials

All chemicals were from Sigma (St. Louis, MO) except the following: [³⁵S]GTPγS (1250 Ci/mmol) was purchased from New England Nuclear Group (Boston, MA), GTPγS from Boehringer Mannheim (New York, NY), and DMEM/F-12 from Fischer Scientific

(Pittsburg, PA). Whatman GF/B glass fiber filters were purchased from Fisher Scientific (Pittsburgh, PA).

5.2.2. Membrane Preparations

Human embryonic kidney-293 cells stably expressing the human CB₁ receptor were cultured in DMEM with 10% fetal bovine serum, and Chinese hamster ovary cells stably expressing the human CB₂ receptor were cultured in DMEM with 10% fetal calf serum. Cells were harvested by replacement of the medium with ice-cold phosphate-buffered saline containing 1 mM EDTA followed by centrifugation at 1000g for 5 min at 4°C. The pellet was resuspended in 50 mM Tris-HCl containing 320 mM sucrose, 2 mM EDTA, and 5 mM MgCl₂, pH 7.4 (centrifugation buffer), and then centrifuged at 1000g for 10 min at 4°C, and the resulting supernatant was saved. This process was repeated twice. The supernatant fractions were combined and centrifuged at 40,000g for 30 min at 4°C. The resulting P2 pellet was resuspended in assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl₂, 0.2 mM EGTA, and 100 mM NaCl), and protein was measured. Membranes were stored at -80°C until use.

5.2.3. Receptor Binding

Membrane homogenates (50 µg) were incubated with 0.5 nM [³H]CP 55,940 in the presence of varying concentrations (1 nM -10 µM) of test compounds in 0.5 mL of buffer containing bovine serum albumin (5 mg/mL). Nonspecific binding was measured in the presence of 1 µM CP 55,940. The assay was incubated at 30°C for 1 h and terminated by the addition of ice-cold 50 mM Tris-HCl containing bovine serum albumin (1 mg/mL, pH 7.4) followed by filtration under vacuum through Whatman GF/B glass fiber filters with three washes with ice-cold Tris buffer. Bound radioactivity was determined by liquid scintillation spectrophotometry at 50% efficiency after extraction by shaking samples for 30 to 60 min with Budget-Solve scintillation fluid.

5.4 [³⁵S]GTPγS Binding

5.4.1 [³⁵S]GTPγS binding assay—Prior to assays, samples were thawed on ice, centrifuged at 50,000 g for 10 minutes at 4 °C, and resuspended in Assay Buffer (50 mM Tris-HCl (pH 7.4), 3 mM MgCl₂, 0.2 mM EGTA, and 100 mM NaCl). Concentration-effect curves were generated by incubating membranes (10 µg) in assay buffer and bovine serum albumin (1 mg/mL) with various concentrations of test compounds in the presence of 20 µM GDP and 0.1 nM [³⁵S]GTPγS in a 1 mL of total volume. [³⁵S]GTPγS binding stimulated by 2 µM CP55,940 was used as an internal standard in each assay. Basal binding was assessed in the absence of agonist, and nonspecific binding was measured in the presence of 10 µM GTPγS. The reaction was incubated for 90 min at 30°C and terminated by filtration under vacuum through Whatman GF/B glass fiber filters with three washes with ice-cold (4°C) Tris buffer (50 mM Tris-HCl, pH 7.4). Bound radioactivity was determined by liquid scintillation spectrophotometry at 95% efficiency after extraction overnight in ScintiSafe Econo 1 scintillation fluid (Fisher Scientific, Hampton, NH).

5.4.2. Data Analysis—All in vitro data are reported as the means ± SEM of at least three experiments, each performed in triplicate. For the receptor binding experiments, displacement IC₅₀ values were originally determined by Hill plots and then converted to K_i values using the method of Cheng and Prusoff.⁴⁷ For the [³⁵S]GTPγS binding experiment, nonlinear regression analysis was conducted to obtain EC₅₀ and E_{max} values of agonist-stimulated [³⁵S]GTPγS binding by iterative curve fitting with JMP (SAS, Cary, NC).

5.3. Pharmacology

5.3.1. Subjects—Male ICR mice (Harlan Laboratories, Dublin, VA) weighing 18–25 g were maintained on a 14:10 hr light:dark cycle with free access to food and water. Δ^9 -THC was obtained from the National Institute on Drug Abuse. All compounds were dissolved in 1:1:18 (emulphor-ethanol-saline) for in vivo administration. Emulphor (EL-620, a polyoxyethylated vegetable oil, GAF Corporation, Linden, NJ) is currently available as Alkmulphor. All drug injections were administered i.v. (tail vein) at a volume of 0.1 mL/10 g of body weight. Following drug administration each animal was tested for effects on the following procedures: spontaneous (locomotor) activity at 5–15 min, tail-flick latency (antinociception) response at 20 min, core (rectal) temperature at 30 min and ring immobility (catalepsy) at 40–45 min. Separate mice were tested with each dose of a compound (n = 6 per dose).

5.3.2. Spontaneous Activity—Measurement of locomotor activity was accomplished by placing mice into individual activity cages (6.5 × 11 in), and recording interruptions of the photocell beams (16 beams per chamber) for a 10-min period using a Digiscan Animal Activity Monitor (Omnitech Electronics Inc., Columbus, OH). Activity in the chamber was recorded as the total number of beam interruptions and was expressed as % inhibition of the level of activity of the vehicle group.

5.4.3. Tail-flick Latency—Antinociception was assessed using the tail-flick procedure. The heat lamp of the tail-flick apparatus was maintained at an intensity sufficient to produce control latencies of 2 to 3 sec. Control values for each animal were determined prior to drug administration. Mice were then re-evaluated following drug administration and latency (sec) to tail-flick response was recorded. A 10-sec maximum was imposed to prevent tissue damage. The degree of antinociception was expressed as the % MPE (maximum possible effect) which was calculated as:

$$\%MPE = \left[\frac{(\text{test latency} - \text{control latency})}{((10 \text{ sec}) - \text{test latency})} \right]$$

5.4.4. Core Temperature—Hypothermia was assessed by first measuring baseline core temperatures prior to drug treatment with a telethermometer (Yellow Springs Instrument Co., Yellow Springs, OH) and a rectal thermistor probe inserted to 25 mm. Rectal temperatures were also measured following drug administration. Rectal temperature values were expressed as the difference between control temperature (before injection) and temperatures following drug administration ($\Delta^\circ\text{C}$).

5.4.5. Catalepsy—Catalepsy was determined by using a slight modification of the ring test as developed by Pertwee.⁴⁸ Mice were injected i.v. with either vehicle or cannabinoid and 40 min after treatment were placed on a ring (5.5 cm in diameter) which was attached to a ringstand and raised to a height of 16 cm. Mice were rated for catalepsy by observers who were blind with regard to treatment. During a 5-min test session, the amount of time (sec) for which the mouse was motionless (except for respiratory movements) was determined. Mice that either fell or actively jumped from the ring were allowed 5 such “escapes.” If these occurred before 2.5 min, the animal’s data were disregarded. An immobility index was determined by dividing the amount of time spent motionless by the length of the test session (300 sec) and multiplying by 100 to determine an immobility index for each mouse.

5.4.6. Data Analysis—When supply of a compound was sufficient to evaluate multiple doses, potency was determined based on a scheme we have used in numerous previous

studies with cannabinoids, with maximal cannabinoid effects in each procedure estimated as follows: 90% inhibition of spontaneous activity, 100% MPE in the tail flick procedure, -6°C change in rectal temperature, and 60% ring immobility. ED_{50} was defined as the dose at which half maximal effect occurred. For compounds that produced one or more cannabinoid effect, ED_{50} was calculated separately using least-squares linear regression on the linear part of the dose-effect curve for each measure in the mouse tetrad, plotted against $\log_{10}$ transformation of the dose. When limited supply prevented assessment of potency, a probe dose of the compound was tested in the in vivo test battery. In these cases, the test dose is specified in the appropriate table and values obtained in each test are reported directly as % inhibition of locomotion, % maximal antinociceptive effect, change in rectal temperature, and % ring immobility.

Acknowledgments

The work at Clemson was supported by grant DA03590 to JWH and that at the Research Triangle Institute by grants DA-031988 and DA-03672 to JLW, all from the National Institute on Drug Abuse.

References and notes

- (1). Gaoni Y, Mechoulam R. *J. Am. Chem. Soc.* 1964; 86:1648.
- (2). (a) Razdan RK. *Pharmacol. Rev.* 1986; 38:75. [PubMed: 3018800] (b) Razdan, RK. *The Cannabinoid Receptors*. Reggio, PH., editor. Humana Press; New York: 2009. p. 3-19.
- (3). Rapaka, RS.; Makriyannis, A. *Structure-Activity Relationships of the Cannabinoids*, NIDA Research Monograph. Vol. 79. National Institute on Drug Abuse; Rockville, MD: 1987.
- (4). Mechoulam, R.; Devane, WA.; Glaser, R. *Marijuana/Cannabinoids: Neurobiology and Neuropsychology*. Murphy, L.; Bartke, A., editors. CRC Press; Boca Raton: 1992. p. 1-33.
- (5). Huffman JW, Lainton JAH. *Curr. Med. Chem.* 1996; 3:101.
- (6). Seltzman HH. *Curr. Med. Chem.* 1999; 6:685. [PubMed: 10469886]
- (7). Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TH. *Nature*. 1990; 346:561. [PubMed: 2165569]
- (8). Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa DR, Rice KC. *Proc. Natl. Acad. Sci. USA*. 1990; 87:1932. [PubMed: 2308954]
- (9). Pertwee RG. *Curr. Med. Chem.* 1999; 6:635. [PubMed: 10469884]
- (10). Munro S, Thomas KL, Abu-Shar M. *Nature (London)*. 1993; 365:61. [PubMed: 7689702]
- (11). Bell MR, D'Ambra TE, Kumar V, Eissenstat MA, Herrmann JL, Wetzel JR, Rosi D, Philion RE, Daum SJ, Hlasta DJ, Kullnig RK, Ackerman JH, Haubrich DR, Luttinger DA, Baizman ER, Miller MS, Ward SJ. *J. Med. Chem.* 1991; 34:1099. [PubMed: 1900533]
- (12). D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward J, Haycock DA, Baizman ER, Casiano FM, Beglin NC, Chippari SM, Grego JD, Kullnig RK, Daley GT. *J. Med. Chem.* 1992; 35:124. [PubMed: 1732519]
- (13). Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR. *J. Pharmacol. Exp. Ther.* 1992; 263:1118. [PubMed: 1335057]
- (14). Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, Ward SJ. *Pharmacol. Biochem. Behav.* 1991; 40:471. [PubMed: 1666911]
- (15). Showalter VM, Compton DR, Martin BR, Abood ME. *J. Pharmacol. Exp. Ther.* 1996; 278:989. [PubMed: 8819477]
- (16). Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, Gruett MD, Kumar V, Estep KG, Olefirowicz EM, Wetzel JR, Alexander MD, Weaver JD, Haycock DA, Luttinger DA, Casiano FM, Chippari SM, Kuster JE, Stevenson JI, Ward SJ. *J. Med. Chem.* 1995; 3094
- (17). Huffman JW, Dai D, Martin BR, Martin BR, Compton DR. *Bioorg. Med. Chem. Lett.* 1994; 4:563.

- (18). Wiley JL, Compton DR, Dai D, Lainton JAH, Phillips M, Huffman JW, Martin BR. J. Pharmacol. Exp. Ther. 1998; 285:995. [PubMed: 9618400]
- (19). Aung MM, Griffin G, Huffman JW, Wu M-J, Keel C, Yang B, Showalter VM, Abood ME, Martin BR. Drug Alcohol Depend. 2000; 60:133. [PubMed: 10940540]
- (20). Huffman JW, Zengin G, Wu M-J, Lu J, Hynd G, Bushell K, Thompson ALS, Bushell S, Tartal C, Hurst DP, Reggio PH, Selley DE, Cassidy MP, Wiley JL, Martin BR. Bioorg. Med. Chem. 2005; 13:89–112. [PubMed: 15582455]
- (21). (a) Huffman JW, Padgett LW. Curr. Med. Chem. 2005; 12:1395–1411. [PubMed: 15974991] (b) Huffman, JW. The Cannabinoid Receptors. Reggio, PH., editor. Humana Press; New York: 2009. p. 49-94.
- (22). Okauchi T, Itonaga M, Minami T, Owa T, Kitoh K, Yoshino H. Org. Lett. 2000; 2:1485. [PubMed: 10814479]
- (23). (a) Huffman JW, Szklennik PV, Almond A, Bushell K, Selley DE, He H, Cassidy MP, Wiley JL, Martin BR. Bioorg. Med. Chem. Lett. 2005; 15:4110–4113. [PubMed: 16005223] (b) Huffman JW, Smith VJ, Padgett LW. Tetrahedron. 2008; 64:2104–2112. [PubMed: 19247425]
- (24). King LC. J. Am. Chem. Soc. 1944; 66:894.
- (25). Whitmore FC, Fox AL. J. Am. Chem. Soc. 1929; 51:3363.
- (26). Bailey RJ, Card P,J, Shecter H. J. Am. Chem. Soc. 1983; 105:6096.
- (27). Rule HG, Barnett JG. J. Chem. Soc. 1932; 175
- (28). Chen J, Smith VJ, Huffman JW. Org. Prep. Proc. Int. 2010; 42:490.
- (29). Tagat JR, McCombie SW, Nazareno DV, Boyle CD, Kozlowski JA, Chackalamannil S, Josien H, Wang Y, Zhou G. J. Org. Chem. 2002; 67:1171. [PubMed: 11846659]
- (30). Smith, VJ. Ph.D. dissertation. Clemson University; 2008 contains the variable temperature ^1H NMR studies for indoles 15 and 16
- (31). Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill H, Saha B, Zerkowski J, Mahadevan A, Razdan RK. J. Pharmacol Exp. Ther. 2006; 318:1230. [PubMed: 16757541]
- (32). Martin, BR.; Compton, DR.; Little, PJ.; Martin, TJ.; Beardsley, PM. Structure Activity Relationships in Cannabinoids. In: Rapaka, RS.; Makriyannis, A., editors. NIDA Research Monograph. Vol. 79. National Institute on Drug Abuse; Rockville, MD: 1987. p. 108-122.
- (33). Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. J. Pharmacol. Exp. Ther. 1988; 247:1046. [PubMed: 2849657]
- (34). Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, Martin BR. J. Pharmacol. Exp. Ther. 1993; 265:218. [PubMed: 8474008]
- (35). Wiley JL, Jefferson RG, Griffin G, Liddle J, Shu Y, Huffman JW, Martin BR. Pharmacology. 2002; 66:89. [PubMed: 12207116]
- (36). Balster RL, Prescott WR. Neurosci. Biobehav. Rev. 1992; 16:55. [PubMed: 1313164]
- (37). Wiley JL, Breivogel CS, Mahadevan A, Pertwee RG, Cascio MG, Bolognini D, Huffman JW, Walentiny DM, Vann RE, Razdan RK, Martin BR. Eur. J. Pharmacol. 2011; 651:96. [PubMed: 21114999]
- (38). Crocker PJ, Mahadevan A, Wiley JL, Martin BR, Razdan RK. Bioorg. Med. Chem. Lett. 2007; 17:1504. [PubMed: 17257842]
- (39). Huffman JW, Mabon R, Wu MJ, Lu J, Hart R, Hurst DP, Reggio PH, Wiley JL, Martin BR. Bioorg. Med. Chem. 2003; 11:539. [PubMed: 12538019]
- (40). Huffman JW, Padgett LW, Isherwood ML, Wiley JL, Martin BR. Bioorg. Med. Chem. Lett. 2006; 16:5432. [PubMed: 16889960]
- (41). Martin BR, Compton DR, Semus SF, Lin S, Marciniak G, Grzybowska J, Charalambous A, Makriyannis A. Pharmacol. Biochem. Behav. 1993; 46:295. [PubMed: 8265683]
- (42). Martin BR, Jefferson R, Winckler R, Wiley JL, Huffman JW, Crocker PJ, Saha B, Razdan RK. J. Pharmacol. Exp. Ther. 1999; 290:1065. [PubMed: 10454479]
- (43). Perumal S, Vasuki G, Wilson DA. Magn. Reson. Chem. 1990; 28:257.
- (44). Dewar MJ, Gridale PJ. J. Am. Chem. Soc. 1962; 84:3541.

- (45). Rajasekaran K, Gnanasekaran C. J. Chem Soc. Perkin Trans. 1987; II:263.
- (46). Ruggli P, Burckhardt E. Helv. Chim. Acta. 1940; 23:441.
- (47). Cheng YC, Prusoff WH. Biochem. Pharmacol. 1973; 22:3099. [PubMed: 4202581]
- (48). Pertwee RG. Br. J. Pharmacol. 1972; 46:753. [PubMed: 4655271]

Scheme 1.

(a) MeMgBr, Et₂O/THF, 0 °C, then ArCOCl, reflux; (b) R'Br, KOH, DMSO, 80 °C; (c) Me₂AlCl, CH₂Cl₂, 30 min, 0 °C, then ArCOCl, 25 °C.

Scheme 2.

(a) CH₃COCl, AlCl₃, ClCH₂CH₂Cl, rt; (b) I₂, pyridine, 100 °C; (c) NaOH/H₂O, reflux, then HCl.

Scheme 3.

(a) NaOH, H₂O then HOAc, Hg(OAc)₂; (b) Br₂/NaBr or I₂/KI, HOAc; (c) 1M NaOH/H₂O, NaCl then HCl; (d) Cl₂, HOAc.

In vitro and in vivo pharmacology of 1-alkyl-3-(4-halo-1-naphthyl)indoles (9 to 12), Δ^9 -THC (1), JWH-015 (5), JWH-018 (4) and WIN-55,212-2 (3)

Table 1

Compound	R	R'	X	K _i (nM)			ED ₅₀ (μmol / kg)			
				CB ₁	CB ₂	Ratio CB ₁ /CB ₂	Tetrad Tests in Mice ^f			
							SA	TF	RT	RI
Δ^9 -THC (1)				41 ± 2 ^a	36 ± 10 ^b	1.1	3.2	4.5	4.5	4.8
WIN-55,212-2 (3)				1.9 ± 0.1 ^b	0.28 ± 0.16 ^b	6.8	0.23 ^c	0.94 ^c	28 ^c	2.8 ^c
JWH-015 (5)				164 ± 22 ^d	13.8 ± 4.6 ^d	11.9	18.7 ^e	84.7 ^e	99.1 ^e	87.2 ^e
JWH-018 (4)				9 ± 5 ^d	2.9 ± 2.6 ^d	3.2	0.44 ^e	0.09 ^e	1.7 ^e	3-9 ^e
JWH-414	C ₃ H ₇	H	F	240 ± 7	33 ± 2	7	67% @ 91	59% @ 91	-3.3 @ 91	Not active
JWH-415	C ₃ H ₇	CH ₃	F	530 ± 37	38 ± 1	14	9.6	11.9	30.1	23.2
Rimonabant (3 mg/kg) blocked or partially blocked all in vivo effects of 30 mg/kg of JWH-415.										
JWH-412	C ₃ H ₁₁	H	F	7.2 ± 0.5	3.2 ± 0.5	2	<0.08	0.14	<0.08	0.58
JWH-413	C ₃ H ₁₁	CH ₃	F	14 ± 0.7	2.2 ± 0.2	6	0.38	0.48	0.54	0.99
JWH-400	C ₃ H ₇	H	Cl	93 ± 8	44 ± 0.4	2	Not tested			
JWH-399	C ₃ H ₇	CH ₃	Cl	187 ± 16	22 ± 1	9	70% @ 83	100% @ 83	-5.4 @ 83	70% @ 83
JWH-398	C ₃ H ₁₁	H	Cl	2.3 ± 0.1	2.8 ± 0.2	0.8	82% @ 27	90% @ 27	-4.9 @ 27	67% @ 27
JWH-397	C ₃ H ₁₁	CH ₃	Cl	8.9 ± 0.3	2.3 ± 0.02	4	94% @ 77	100% @ 77	-6.4 @ 77	88% @ 77
JWH-386	C ₃ H ₇	H	Br	161 ± 16	27 ± 1.6	6	71% @ 77	75% @ 77	-3.9 @ 77	26% @ 77
JWH-395	C ₃ H ₇	CH ₃	Br	373 ± 43	31 ± 2	12	80% @ 74	96% @ 74	-5.0 @ 74	50% @ 74
JWH-387	C ₃ H ₁₁	H	Br	1.2 ± 0.1	1.1 ± 0.1	1	Not tested			
JWH-394	C ₃ H ₁₁	CH ₃	Br	14 ± 0.2	2.8 ± 0.2	5	Not tested			
JWH-423	C ₃ H ₇	H	I	140 ± 10	6.6 ± 0.2	21	10% @ 6.8	26% @ 6.8	-1.7 @ 6.8	2% @ 6.8

Compound	K _i (nM)					ED ₅₀ (μmol / kg)			
	R	R'	X	CB ₁	CB ₂	Ratio CB ₁ /CB ₂	Tetrad Tests in Mice ^f		
							SA	TF	RT
JWH-422	C ₃ H ₇	CH ₃	I	501 ± 48	20 ± 0.4	25	74% @ 66	60% @ 66	-3.0 @ 66
JWH-421	C ₃ H ₁₁	H	I	2.5 ± 0.2	1.3 ± 0.02	2	0.30	0.45	0.19
JWH-420	C ₃ H ₁₁	CH ₃	I	14 ± 1	2.1 ± 0.1	7	1.1	2.5	2.6

(RT), and ring immobility (RI).

^aRef 41

^bRef 15

^cRef 14

^dRef 20

^eRef 18

^fPharmacological tests in mice included spontaneous activity (SA), tail flick test of antinociception (TF), change in rectal temperature

Table 2Receptor affinities (mean $\pm$ SEM) of 1-alkyl-3-(8-halo-1-naphthoyl)indoles (14 to 16)

Compound	R	R'	X	K _i (nM)			ED ₅₀ (μmol / kg)			
				CB ₁	CB ₂	Ratio CB ₁ /CB ₂	SA	TF	RT	RI
JWH-456	C ₃ H ₇	H	Cl	642 $\pm$ 50	134 $\pm$ 20	4.8	68% @ 86	72% @ 86	Not active @ 86	
JWH-461	C ₃ H ₇	CH ₃	Cl	>10,000	174 $\pm$ 29	>57	70% @ 83	42% @ 83	-2.3 @ 83	15% @ 83
JWH-457	C ₃ H ₁₁	H	Cl	23 $\pm$ 1	10 $\pm$ 0.8	2.3	94% @ 80	100% @ 80	-6.9 @ 80	92% @ 80
JWH-462	C ₅ H ₁₁	CH ₃	Cl	116 $\pm$ 7	19 $\pm$ 1.6	6.1	84% @ 77	100% @ 77	-5.5 @ 77	86% @ 77
JWH-428	C ₃ H ₇	H	Br	>10,000	192 $\pm$ 14	>52	76% @ 77	9% @ 77	-2 @ 77	5% @ 77
JWH-429	C ₃ H ₇	CH ₃	Br	>10,000	278 $\pm$ 69	>36	49% @ 74	72% @ 74	-2.3 @ 74	4% @ 74
JWH-424	C ₃ H ₁₁	H	Br	21 $\pm$ 3.4	5.4 $\pm$ 0.2	4	1.4	1.8	2.4	3.7
JWH-425	C ₅ H ₁₁	CH ₃	Br	54 $\pm$ 11	10 $\pm$ 0.4	5.5	79% @ 6.9	100% @ 6.9	-3.7 @ 6.9	53% @ 6.9
JWH-419	C ₃ H ₇	H	I	2960 $\pm$ 240	152 $\pm$ 33	19	-25% @ 68	Not active @ 68		
JWH-418	C ₃ H ₇	CH ₃	I	4290 $\pm$ 440	536 $\pm$ 66	8		Not active @ 66		
JWH-416	C ₅ H ₁₁	H	I	73 $\pm$ 10	3.3 $\pm$ 0.1	22	1.8	1.3	-6.4	3.6
JWH-417	C ₅ H ₁₁	CH ₃	I	522 $\pm$ 58	13 $\pm$ 0.2	40		Not active @ 6.2		